KR101706817B1 - Composition comprising radish leave extract for anti-inflammatory and anti-oxidant - Google Patents
Composition comprising radish leave extract for anti-inflammatory and anti-oxidant Download PDFInfo
- Publication number
- KR101706817B1 KR101706817B1 KR1020140046766A KR20140046766A KR101706817B1 KR 101706817 B1 KR101706817 B1 KR 101706817B1 KR 1020140046766 A KR1020140046766 A KR 1020140046766A KR 20140046766 A KR20140046766 A KR 20140046766A KR 101706817 B1 KR101706817 B1 KR 101706817B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- inflammation
- inflammatory
- activity
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000284 extract Substances 0.000 title claims abstract description 78
- 239000000203 mixture Substances 0.000 title claims abstract description 19
- 230000003078 antioxidant effect Effects 0.000 title abstract description 38
- 230000003110 anti-inflammatory effect Effects 0.000 title abstract description 5
- 239000003963 antioxidant agent Substances 0.000 title description 18
- 235000006708 antioxidants Nutrition 0.000 title description 18
- 241000220259 Raphanus Species 0.000 title description 13
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 title description 13
- 239000000843 powder Substances 0.000 claims abstract description 36
- 206010061218 Inflammation Diseases 0.000 claims abstract description 28
- 230000003064 anti-oxidating effect Effects 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 13
- 238000000605 extraction Methods 0.000 claims description 8
- 239000012141 concentrate Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract description 27
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract description 27
- 230000000694 effects Effects 0.000 abstract description 27
- 235000005911 diet Nutrition 0.000 abstract description 24
- 230000037213 diet Effects 0.000 abstract description 9
- 238000010298 pulverizing process Methods 0.000 abstract description 6
- 235000007882 dietary composition Nutrition 0.000 abstract description 3
- 240000006439 Aspergillus oryzae Species 0.000 abstract 1
- 235000002247 Aspergillus oryzae Nutrition 0.000 abstract 1
- 239000000287 crude extract Substances 0.000 abstract 1
- 235000013305 food Nutrition 0.000 description 34
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 25
- 230000004054 inflammatory process Effects 0.000 description 23
- 239000000523 sample Substances 0.000 description 20
- 206010009887 colitis Diseases 0.000 description 18
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 17
- 210000001072 colon Anatomy 0.000 description 16
- 230000006698 induction Effects 0.000 description 16
- 230000000378 dietary effect Effects 0.000 description 15
- 229930003935 flavonoid Natural products 0.000 description 15
- 235000017173 flavonoids Nutrition 0.000 description 15
- 235000013824 polyphenols Nutrition 0.000 description 15
- 150000008442 polyphenolic compounds Chemical class 0.000 description 14
- 235000019786 weight gain Nutrition 0.000 description 14
- 150000002215 flavonoids Chemical class 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 230000002292 Radical scavenging effect Effects 0.000 description 12
- 238000002835 absorbance Methods 0.000 description 12
- 230000004584 weight gain Effects 0.000 description 12
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 11
- 235000013311 vegetables Nutrition 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 235000018823 dietary intake Nutrition 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 9
- 210000004969 inflammatory cell Anatomy 0.000 description 8
- 230000002757 inflammatory effect Effects 0.000 description 8
- 230000000968 intestinal effect Effects 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- -1 rope Substances 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 102000019197 Superoxide Dismutase Human genes 0.000 description 6
- 108010012715 Superoxide dismutase Proteins 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 238000011088 calibration curve Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 235000012631 food intake Nutrition 0.000 description 6
- 230000037406 food intake Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 235000010323 ascorbic acid Nutrition 0.000 description 5
- 239000011668 ascorbic acid Substances 0.000 description 5
- 229960005070 ascorbic acid Drugs 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000008951 colonic inflammation Effects 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 238000004108 freeze drying Methods 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 description 5
- 239000011707 mineral Substances 0.000 description 5
- 235000010755 mineral Nutrition 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 235000019154 vitamin C Nutrition 0.000 description 5
- 239000011718 vitamin C Substances 0.000 description 5
- 206010009944 Colon cancer Diseases 0.000 description 4
- 208000011231 Crohn disease Diseases 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 240000007058 Halophila ovalis Species 0.000 description 4
- 235000019057 Raphanus caudatus Nutrition 0.000 description 4
- 244000088415 Raphanus sativus Species 0.000 description 4
- 235000011380 Raphanus sativus Nutrition 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 235000020940 control diet Nutrition 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 4
- 235000020188 drinking water Nutrition 0.000 description 4
- 239000003651 drinking water Substances 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 230000036542 oxidative stress Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- 101100449517 Arabidopsis thaliana GRH1 gene Proteins 0.000 description 3
- 241001474374 Blennius Species 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 101100434479 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) AFB1 gene Proteins 0.000 description 3
- 241000209140 Triticum Species 0.000 description 3
- 235000021307 Triticum Nutrition 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- OQIQSTLJSLGHID-WNWIJWBNSA-N aflatoxin B1 Chemical compound C=1([C@@H]2C=CO[C@@H]2OC=1C=C(C1=2)OC)C=2OC(=O)C2=C1CCC2=O OQIQSTLJSLGHID-WNWIJWBNSA-N 0.000 description 3
- 229930020125 aflatoxin-B1 Natural products 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229930002875 chlorophyll Natural products 0.000 description 3
- 235000019804 chlorophyll Nutrition 0.000 description 3
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 3
- 238000010411 cooking Methods 0.000 description 3
- 230000018044 dehydration Effects 0.000 description 3
- 238000006297 dehydration reaction Methods 0.000 description 3
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000003871 intestinal function Effects 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 235000019155 vitamin A Nutrition 0.000 description 3
- 239000011719 vitamin A Substances 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- 125000006306 4-iodophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1I 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 102000013142 Amylases Human genes 0.000 description 2
- 108010065511 Amylases Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000589989 Helicobacter Species 0.000 description 2
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 241000121220 Tricholoma matsutake Species 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 235000021120 animal protein Nutrition 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 238000009360 aquaculture Methods 0.000 description 2
- 244000144974 aquaculture Species 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 229940111205 diastase Drugs 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 2
- 239000013024 dilution buffer Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 2
- 235000011957 flavonols Nutrition 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000007661 gastrointestinal function Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000000260 hypercholesteremic effect Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 238000010197 meta-analysis Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 2
- 238000003359 percent control normalization Methods 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 2
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 2
- 229960001940 sulfasalazine Drugs 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 241001300301 uncultured bacterium Species 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- 208000019399 Colonic disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- 244000285955 Cyrtosperma chamissonis Species 0.000 description 1
- 235000005885 Cyrtosperma chamissonis Nutrition 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- 235000008597 Diospyros kaki Nutrition 0.000 description 1
- 101100449439 Drosophila melanogaster grass gene Proteins 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 241000164875 Firmicutes bacterium Species 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102000001284 I-kappa-B kinase Human genes 0.000 description 1
- 108060006678 I-kappa-B kinase Proteins 0.000 description 1
- 206010061217 Infestation Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 244000294611 Punica granatum Species 0.000 description 1
- 235000014360 Punica granatum Nutrition 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 241000223253 Rhodotorula glutinis Species 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 240000003377 Shepherdia canadensis Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000300264 Spinacia oleracea Species 0.000 description 1
- 235000009337 Spinacia oleracea Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- ZTOJFFHGPLIVKC-CLFAGFIQSA-N abts Chemical compound S/1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C\1=N\N=C1/SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-CLFAGFIQSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- ZOJBYZNEUISWFT-UHFFFAOYSA-N allyl isothiocyanate Chemical compound C=CCN=C=S ZOJBYZNEUISWFT-UHFFFAOYSA-N 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 238000013130 cardiovascular surgery Methods 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 230000008508 epithelial proliferation Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000004090 etiopathogenesis Effects 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 150000007946 flavonol Chemical class 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- PHMDYZQXPPOZDG-UHFFFAOYSA-N gallane Chemical compound [GaH3] PHMDYZQXPPOZDG-UHFFFAOYSA-N 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 235000002044 guayabota nspero Nutrition 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N methyl mercaptane Natural products SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000008164 mustard oil Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 229940027779 persimmon extract Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 229940079877 pyrogallol Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- VHYHKZFQXUYNSG-UHFFFAOYSA-M sodium;4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-1,3-dihydrotetrazol-3-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[NH+](C=2C=CC(I)=CC=2)N=C(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)N1 VHYHKZFQXUYNSG-UHFFFAOYSA-M 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000021404 traditional food Nutrition 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Images
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Medicines Containing Plant Substances (AREA)
- Mycology (AREA)
- Physiology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
무청 추출물의 항산화 및 항염 활성 및 궤양성 대장염 예방 효과를 갖는 무청 추출물을 분말화한 추출분말을 함유하는 사료용 식이조성물에 관한 것으로서, 무청 추출물을 포함하는 추출분말을 유효활성성분으로 포함함을 특징으로 하는 항염 및 항산화를 위한 사료조성물이 개시된다.The present invention relates to a dietary composition for diets containing an extract powder obtained by pulverizing a crude extract having the antioxidative and antiinflammatory activity and the ulcerative colitis-preventing effect of the extract of Aspergillus oryzae, A feed composition for anti-inflammation and antioxidation.
Description
본 발명은 무청 추출물을 포함하는 항염 및 항산화를 위한 사료조성물에 관한 것으로 특히, 상기 무청 추출물의 항산화 및 항염 활성 및 궤양성 대장염 예방 효과를 갖는 무청 추출물 또는 상기 무청 추출물을 분말화한 추출분말을 함유하는 사료용 식이조성물에 관한 것이다.The present invention relates to a feed composition for anti-inflammation and antioxidation comprising an extract of Wujing, and more particularly to a composition for preventing or treating antioxidative and anti-inflammatory activity and ulcerative colitis of the Wujing extract or an extract powder obtained by pulverizing the Wujing extract To a dietary composition for feed use.
염증성 장질환(Inflammatory bowel disease ; IBD)은 대장암 발생의 대표적인 고위험 질환으로(문헌 Terzic J, Grivennikov S, Karin E, Karin M. 2010. Inflammation and colon cancer. Gastroenterology 138:2101-14 e5 참조), 병변과 염증증상의 차이에 따라 궤양성 대장염(Ulcerative colitis, UC)와 크론병(Crohn's disease, CD)로 나뉜다(문헌 Fiocchi C. 1998. Inflammatory bowel disease ; etiology and pathogenesis. Gastroenterology. 115 : 182-205 참조). 둘 다 완치가 힘들고 호전과 악화를 반복하며, 체중감소, 혈액을 동반한 설사, 발열, 장 운동장애, 결장의 단축 같은 유사한 병리학적 징후를 보인다(문헌 Hendrickson BA, Gokhale R, Cho JH. 2000. Clinical aspects and pathophysiology of inflammatory bowel diesease. Clin Microbiol Rev. 15(1) : 79-94 참조).Inflammatory bowel disease (IBD) is a common high-risk disease of colon cancer (see Terzic J, Grivennikov S, Karin E, Karin M. 2010. Inflammation and colon cancer. Gastroenterology 138: 2101-14e5) The ulcerative colitis (UC) and Crohn's disease (CD) are divided according to the lesion and inflammatory symptoms (Fiocchi C. 1998. Inflammatory bowel disease, etiology and pathogenesis. Gastroenterology. 115: 182-205 Reference). Both are difficult to cure and repeat improvement and deterioration, and have similar pathological signs such as weight loss, diarrhea with blood, fever, intestinal motility disorder, and shortening of the colon (Hendrickson BA, Gokhale R, Cho JH 2000. Clinical aspects and pathophysiology of inflammatory bowel diesease. Clin Microbiol Rev. 15 (1): 79-94).
특히 UC의 경우, 대규모 역학조사는 시행되지 않았지만, 서울 송파-강동구를 표본으로 한 조사에서 UC의 발병률은 1986-1988년경에 인구 10만명당 0.2명이던 것이(문헌 Chang DK, Kim YH, Byeon JS, Yang SK, Chung YW, Han DS, Kim SG, Kim TI, Kin WH, Jeen YT, Eun CS, Choi H, Choi KY, Song IS. 2005. The current states of ulcerative colitis-associated colorectal cancer in Korea: a KASID study. Korean J Gastroenterol. 46(4) : 276-282 참조), 1995-1997년 사이에 1.23명으로 상승하였으며 2001-2005년에는 인구 10만명당 3.08명으로 증가한 것이 관찰되었다(문헌 Yang SK, Hong WS, Min YI. 2000. Incidence and prevalence of uncerative colitis in the Songpa-Kangdong District, Seoul, Korea. 1986-1997. J Gastroenterol Hepatol 15 : 1037-1042 참조). 유병률 역시 1997년 인구 10만명 당 7.57명에서 2005년에는 30.87명으로 가파르게 상승하였다(문헌 Yang SK, Yun S, Kim JH, Park JY, Kim YH, Chang DK, Kim JS, Song PS, Park JB, Park ER, Kim KJ, Moon G, Yang SH. 2008. Epidemiology of Inflammatory Bowel Disease in the Songpa-Kangdong District, Seoul, Korea, 1986 2005: A KASID Study. Inflammatory bowel diseases 14(4) : 542-549 참조). 북미의 경우 연간 발생률이 인구 10만명 당 6.0-15.6명, 유렵의 경우 1.5-20.3명으로 나타났으며, 유병률은 지역에 따라 21.4-246명으로 보고되어(문헌 Loftus E. 2004. Clinical epidemiology of inflammatory bowel disease : incidence, prevalence and environmental influences. Gastroenterology 126(6) : 1504-1517 참조), 한국의 UC 유병률은 북미, 유럽의 발병률에 비하면 흔치 않은 질병이라 할 수 있지만 지속적으로 증가하고 있는 추세를 볼 때 조만간 비슷해지리라 예상한다(문헌 Yang SK. 2002. Current status and clinical characteristics of inflammatory bowel disease in Korea. Korean J Gastroenterol. 40(1) : 1-4 참조). In particular, UC has not been subjected to a large-scale epidemiological survey, but the incidence of UC was 0.2 per 100,000 population in 1986-1988 (Chang DK, Kim YH, Byeon JS, The present state of ulcerative colitis-associated colorectal cancer in Korea: a KASID (Korean Society for Thoracic and Cardiovascular Surgery), Seoul, Korea. study, Korean J Gastroenterol. 46 (4): 276-282), increased to 1.23 persons between 1995 and 1997, and increased to 3.08 persons per 100,000 population between 2001 and 2005 (Yang SK, Hong WS , Min YI, 2000. Incidence and prevalence of uncer- tative colitis in the Songpa-Kangdong District, Seoul, Korea, 1986-1997 J Gastroenterol Hepatol 15: 1037-1042). The prevalence also increased steeply from 7.57 per 100,000 population in 1997 to 30.87 in 2005 (Yang SK, Yun S, Kim JH, Park JY, Kim YH, Chang DK, Kim JS, Song PS, Park JB, Park (KASID Study, Inflammatory Bowel Diseases 14 (4): 542-549). In this study, we compared the incidence of infarcted bowel disease with the incidence of infectious diseases in Korea. In North America, the annual incidence was 6.0-15.6 per 100,000 population and 1.5-20.3 in Europe, and the prevalence was reported to be 21.4-246 according to the region (Loftus E. 2004. Clinical epidemiology of inflammatory Gastroenterology 126 (6): 1504-1517), and the prevalence of UC in Korea is an uncommon disease compared to the incidence in North America and Europe, but the trend is steadily increasing (Yang SK, 2002. Current status and clinical characteristics of inflammatory bowel disease in Korea. Korean J Gastroenterol 40 (1): 1-4).
이에 따라 많은 치료제가 사용되고 있으며, 이 중 궤양성 대장염(Ulcerative colitis, UC)의 치료제로 글루코코르티코이드(glucocorticoid)(문헌 Boumpas DT, Chrousos GP, Wilder RL. 1993. Glucocorticoid therapy for immune-mediated diseases:basic and clinical correlates. AnnIntern Med 119 : 1198-1208 참조)와 설파살라진(sulfasalazine)(문헌 Msiewicz JJ, Lennard-hones JE, Connell AM. 1965. Controlled trial of sulfasalazine in maintenance therapy for ulcerative colitis. Lancet:185-188 참조) 등이 사용되고 있으나, 장내 유용한 세균총들을 죽이고 구역질, 구토, 소화불량, 식욕부진 및 두드러기, 발열, 간염, 용혈성 빈혈, 골수 억제 등의 부작용을 일으키며(문헌 Das KM, Eastwood MA, McManus JP, Sircus W. 1973. Adverse reactions during salicylazosulphapyridine therapy and the relation with drug metabolism and acetylator phenotype. M Engl J Med 289 : 491-495; Dignass A, Layer P. 1995. Inflammatory bowel Diseases : New Developments and Standards, Dordrecht : Kluwer Acadenic Publishers. 183-192 참조), 궤양성 대장염은 이환된 지 30년 이내에 18%의 환자에서 대장암이 발생한다(문헌 Canavan C, Abrams KR, Mayberry J. 2006. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease. Aliment Pharmacol Ther 23:1097-104 참조)는 연구결과가 보고되면서(문헌 Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48:526-35 참조), 이를 예방할 수 있는 대안책을 필요로 한다(문헌 Ullman T, Croog V, Harpaz N, Sachar D, Itzkowitz S. 2003. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology 125 : 1311-1319 참조).Many therapeutic agents have been used for this purpose, and glucocorticoids (Boumpas DT, Chrousos GP, Wilder RL, 1993. Glucocorticoid therapy for immune-mediated diseases: basic and therapeutic agents for ulcerative colitis (UC) Clinical correlates. Ann Intern Med 119: 1198-1208) and sulfasalazine (Msiewicz JJ, Lennard-hones JE, Connell AM, 1965. Controlled trial of sulfasalazine in maintenance therapy for ulcerative colitis. Lancet: 185-188) But it also causes side effects such as nausea, vomiting, dyspepsia, anorexia and urticaria, fever, hepatitis, hemolytic anemia, bone marrow suppression, and the like, by killing useful bacterial guns in the intestine (Das KM, Eastwood MA, McManus JP, Sircus W. 1973. Adverse reactions during salicylazosulphapyridine therapy and the relationship with drug metabolism and acetylator phenotype M Engl J Med 289: 491-495; Dignassa, Layer P. 1995. Inflammatory bo ulcerative colitis occurs in 18% of patients within 30 years of the disease (Canavan C, Abrams KR, Mayberry J < RTI ID = 0.0 > 2006. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease. Aliment Pharmacol Ther 23: 1097-104) have been reported (Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48: 526-35 (Ullman T, Croog V, Harpaz N, Sachar D, Itzkowitz S. 2003. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology 125: 1311 -1319).
궤양성 대장염은 여러 가지 환경적 요인과 유전적 요인이 복합적으로 작용하여 발생한다고 하지만, 주된 발병요인은 아직 명확하게 밝혀지지 않은 상태이다. 그러나, 일본의 경우, 육류와 유제품 등의 동물성 단백질의 소비가 증가하기 시작한 1960년대부터 궤양성 대장염의 발생이 증가하였으며(문헌 Yosida Y, Murata Y. 1990. Inflammatory bowel disease in Japan : studies of epidemiology and etiopathogenesis. Med Clin North Am 74 : 67-90 참조), 우리나라 역시 1인당 1일 동물성 단백질의 섭취량이 증가한 1980년대부터 1990년대 중반까지 궤양성 대장염의 발생이 증가(문헌 Ministry of Health & Welfare. 1990. Report on 1998 national health and nutrition survey(dietary intake survey). 38-140 참조)한 점이나, 저개발 국가보다는 미국이나 유럽과 같이 산업화된 국가에서 더 많이 발생하고, 저개발 국가도 경제가 성장함에 따라 발병률이 증가하는 것으로 볼 때, 필요이상의 열량과 동물성 식품의 섭취 그리고 채소와 과일을 포함한 식물성 식품의 적은 섭취로 변화된 식습관이 궤양성 대장염과 밀접하게 관련이 있다고 본다(문헌 Doll R, Peto R. 1981. The causes of cancer. Quantitative estimates of avoidable risks of cancer in the Unitede States today. J Natl Cancer Inst 66 : 1191-1308 참조). Ulcerative colitis is caused by a combination of various environmental factors and genetic factors. However, the main cause of ulcerative colitis is still unclear. However, in Japan, the incidence of ulcerative colitis has increased since the 1960s when consumption of animal proteins such as meat and dairy products began to increase (Yosida Y, Murata Y. 1990. Inflammatory bowel disease in Japan: studies of epidemiology and etiopathogenesis. Med Clin North Am 74: 67-90). In Korea, the incidence of ulcerative colitis increased from 1980 to the mid 1990s when the daily intake of animal protein per person increased (Ministry of Health & Welfare. (See also Report on 1998 national health and nutrition survey, pp. 38-140), but it is more prevalent in industrialized countries such as the US and Europe than in underdeveloped countries, Increasingly, dietary habits have been altered by the consumption of more calories than necessary and the consumption of animal foods and the low intake of vegetable foods, including vegetables and fruits I believe the closely related benign colitis (literature Doll R, Peto R. 1981. The causes of cancer Quantitative estimates of avoidable risks of cancer in the Unitede States today J Natl Cancer Inst 66: 1191-1308, see.).
리프(Rief) 등은 지방의 섭취가 궤양성대장염 발병 증가와 관련이 있으며, 과일, 채소와 식이섬유의 섭취가 이를 감소시킨다고 보고하였고(문헌 Rief S, Klein I, Lubin F, Farbstein M, Hallak A, Gilat T. 1997. Pre-illness dietary factors in inflammatory bowel disease. Gut 40(6) : 754-760 참조), 또 다른 연구에서는 환자군-대조군 비교연구를 통해 UC의 발병을 증가시키는 요인으로 과도한 당류섭취를 꼽았다(문헌 Sakamoto N, Kono S, Wak ai K, Fukuda Y, Satomi M, Shimoyama T, Inada Y, Miyake Y, Sasaki S, Okamoto K, Kobashi G, Washio M, Yokoyama T, Date C, Tanaka H. 2005. Dietary risk factors for inflammatory bowel disease : a multicenter case-control study in Japan. Inflamm Bowel Dis 11(2) : 154-163 참조). Rief et al. Reported that fat intake was associated with an increased incidence of ulcerative colitis, and that intake of fruits, vegetables and dietary fiber reduced this (Rief S, Klein I, Lubin F, Farbstein M, Hallake , Gilat T., 1997. Gut 40 (6): 754-760). In another study, a comparative study of patient-control groups showed that excessive sugar intake (Sakamoto N, Kono S, Wakai K, Fukuda Y, Satomi M, Shimoyama T, Inada Y, Miyake Y, Sasaki S, Okamoto K, Kobashi G, Washio M, Yokoyama T. Date C, Tanaka H. 2005. Dietary risk factors for inflammatory bowel disease: a multicenter case-control study in Japan. Inflamm Bowel Dis 11 (2): 154-163).
궤양성 대장염의 염증반응은 체내에서 발생한 산화스트레스에 의해 촉진된다(문헌 최수연. 2004. 일반식이와 고지방식이에서 quercetin 또는 -carotene 보충이 화학적으로 유도된 대장암의 발생과 대장점막 염증반응에 미치는 효과에 관한 연구. 박사학위논문, 숙명여자대학교 대학원. 참조). 산화스트레스는 활성산소종(ROS ; reactive oxygen species)를 만드는데, ROS는 세포 내 DNA, 단백질, 지질, 탄수화물 등의 거대분자들과 반응하여 DNA분절, 단백질의 불활성화, 불포화 지방산의 과산화 등의 문제를 낳아 생체기능을 저하 시킨다(문헌 Volko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J, 2007. Free radicals and antioxidants in normal physiological functons and human disease. nt J. Biochem Cell Biol 39 : 44-84 참조). ROS가 과잉 축적되면 DNA와 세포내 여러 분자에 손상을 가져오므로 이를 개선하기 위해 체내에는 항산화 시스템이 존재한다(문헌 Andersen HR, Nielsen JB, Nielsen F, Grandjean P. 1997. Antioxidative enzyme activities in human erythrocytes. Clin. Chem. 43 : 562-568 참조). 항산화 시스템의 주요 구성성분은 비타민 C, E, A와 무기질, 카로테노이드(carotenoid)와 같은 기능성 물질들로, 대부분 식물성 식품을 통해 얻을 수 있다. The inflammatory response of ulcerative colitis is promoted by oxidative stress in the body (Choi, Su-Yeon, 2004. In the general diet and high-fat diets, quercetin or -carotene supplementation is associated with chemically induced colon cancer development and colonic mucosal inflammatory response A study on the effects of the research. Oxidative stress produces reactive oxygen species (ROS), which react with macromolecules such as intracellular DNA, proteins, lipids, and carbohydrates to cause DNA segmentation, inactivation of proteins, and peroxidation of unsaturated fatty acids (Volko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J, 2007. Free radicals and antioxidants in normal physiological func- tions and human disease. Nt J. Biochem Cell Biol 39: 44 -84). An excess accumulation of ROS causes damage to DNA and various molecules in the cell. Therefore, there is an antioxidant system in the body to improve it (Andersen HR, Nielsen JB, Nielsen F, Grandjean P. 1997. Antioxidative enzyme activities in human erythrocytes Clin. Chem. 43: 562-568). The main components of the antioxidant system are functional substances such as vitamins C, E, A and minerals and carotenoids, most of which can be obtained from plant foods.
즉, 식물성 식품의 섭취는 인체의 항산화 수준에 긍정적인 영향을 미치며(문헌 Liu RH, Finley J. Potential cell culture models for antioxidant research. 2005. J Agric Food Chem 53 : 4311-4314 참조), 이는 식물성 식품보다 동물성 식품의 비중이 높은 사람일수록 항산화 체계가 불균형하다는 것이다. 따라서 궤양성 대장염의 예방 및 치료를 위해서는 식단 내 식물성 식품의 비중을 높이는 것이 중요하다.That is, the intake of vegetable foods has a positive effect on the antioxidant level of the human body (Liu RH, Finley J. Potential cell culture models for antioxidant research, 2005. J Agric Food Chem 53: 4311-4314) The higher the proportion of animal food is, the more unbalanced the antioxidant system. Therefore, it is important to increase the proportion of vegetable foods in the diet for prevention and treatment of ulcerative colitis.
이러한 노력에도 불구하고 자연계에는 아직도 알려지지 않은 무수한 항산화 물질이 존재하고 있으며, 따라서 보다 우수한 항산화 활성을 지니는 천연 항산화 소재에 대한 연구 및 개발의 필요성은 날로 증대되고 있다.Despite these efforts, there is still a myriad of unknown antioxidants in the natural world. Therefore, the need for research and development of natural antioxidant materials with better antioxidant activity is increasing day by day.
무(Radish)는 뿌리와 잎에 비타민 등과 같은 다량의 영양소를 함유하고 있는 주요 채소류의 하나이다. 특히 무잎에는 광합성 작용을 하는 엽록소가 넓게 분포되어 있고 당질 함량이 낮은 반면, 비타민 A, B1, B2, C, 나이아신, 단백질, 지질(脂質) 및 철분, 칼슘이 골고루 함유되어 있을 뿐 아니라, 풍부한 섬유질 식품으로 성인병 예방에도 좋은 것으로 알려져 있으며, 최근 연구에 따르면 비만, 변비의 치료에 유용하고, 전분 분해효소인 디아스타아제(Diastase) 성분이 함유되어 있어서 위장에도 유익한 것으로 보고되고 있어 우리네 식단에서 매우 중요한 위치를 차지하고 있다. 무청은 무(Radish) 뿌리의 윗부분 즉, 줄기와 잎부분에 해당하며, 이를 건조시킨 시래기(시래기 및/또는 무거지; 이하에서는 무청으로 통일하여 기재함)는 우리 국민 대부분이 좋아하는 기호식품이지만 수확시기가 한정되어 있을 뿐 아니라 년중 상식(常食)할 수 있게 상품화되어 있지 못한 관계로 여타의 다른 전통식품들처럼 상품으로서의 역할을 다하지 못하고 있는 실정이다. 상기 시래기 제조과정을 살펴보면, 무로부터 채취된 생(生)무청을 짚이나 새끼줄, 나이론 끈 등으로 엮은 다음, 적당한 장소에 매달아 자연 건조시킨 후, 보관하면서 필요할 때 삶아 식용하는 전근대적인 방법에 의존하고 있어서 영양 손실이 많은 편이고, 또한 비위생적이어서 먹거리로서의 가치가 크게 떨어질 수밖에 없다. 이러한 점을 고려하여 무청을 활용할 수 있는 다양한 식품 제조방법들이 제안되고 있으나, 제조원가가 비싸고 상품성이 떨어져 대중화와는 거리가 먼 실정이다.Radish is one of the major vegetables that contain large amounts of nutrients such as vitamins in roots and leaves. In particular, leafless chlorophyll is widely distributed on the leafless leaves and has a low sugar content, while vitamin A, B1, B2, C, niacin, protein, lipid, iron and calcium are uniformly distributed, It is known that it is good for prevention of adult diseases by food. According to recent research, it is useful for the treatment of obesity and constipation, and it is reported to be beneficial for gastrointestinal because it is contained starch hydrolyzate diastase (diastase) It is occupied. Wuchung is the upper part of the radish root, stem and leaf part, and the dried seagrass (seagrass and / or non-seaweed) is the favorite food of most of the Korean people In addition to being limited in harvest time, it has not been commercialized so that it can be commonly consumed throughout the year. Therefore, it does not fulfill its role as a commodity like other traditional foods. As for the process of manufacturing the seagrass, the raw seaweed collected from radishes is knitted with straw, rope, nylon string, hanging in a proper place, naturally dried, and then relying on a pre-modern method There is a lot of nutrition loss, and because it is unsanitary, the value of food is inevitably falling. In consideration of this point, various food manufacturing methods that can utilize Wuqing have been proposed, but the manufacturing cost is expensive and the commerciality is poor, which is far from popularization.
한국 공개특허 제2004-0011578호는 무청을 이용한 식품 제조방법을 기술하고 있으며, 여기에서는 생(生)무청을 장기간 보관하면서 언제나 즐길 수 있는 상품(건식의 시래기 및/또는 습식의 무우거지)으로 상식화(常食化), 대중화 할 수 있으며, 양념이 같이 포장되어 소비자의 기호에 맞게 국이나, 찌개용 또는 이에 첨가하여 바로 조리해 먹을 수 있도록 한다는 내용이 기재되어 있다.Korean Patent Laid-Open Publication No. 2004-0011578 describes a method of producing food using mushrooms. Here, a method of producing food using mushrooms is described in which products (dry seaweeds and / or wet dairy cows) (Regularized), can be popularized, and packaged together with spices, according to the taste of the consumer, chikenjyeon, or added to the cooked food is described in the description.
본 발명은 무청 추출물의 항산화 및 항염 활성 및 궤양성 대장염 예방 효과를 갖는 무청 추출물 또는 상기 무청 추출물을 분말화한 추출분말을 함유하는 식이조성물을 제공하는데 그 목적이 있다.It is an object of the present invention to provide a dietary composition containing an aspartic acid extract having an antioxidative and anti-inflammatory activity and an ulcerative colitis-preventing effect, or an extract powder obtained by pulverizing the aspartame extract.
본 발명에 따른 무청 추출물을 포함하는 항염 및 항산화를 위한 조성물은, 무청 추출물은 무청을 추출하여 제조되며, 이때 추출비율은 무청의 70% 내지 90%(v/v)인 에탄올 90 내지 99중량% 및 상기 무청의 건조분말 1 내지 10중량%의 비율로 혼합하고, 상온에서 40 내지 54시간 동안 현탁시킨 후, 다시 20 내지 28시간 동안 침지시킨 후, 여과하는 과정을 1 내지 5번 반복하여 얻은 추출물을 합하여 1 내지 20℃의 온도조건에서 농축시킨 것일 수 있다.The composition for anti-inflammation and antioxidation according to the present invention is prepared by extracting the extracts of Wuchung, wherein the extraction ratio is 90 to 99% by weight of ethanol with 70 to 90% (v / v) And 1 to 10% by weight of the crude dry powder, suspending the mixture at room temperature for 40 to 54 hours, further immersing the mixture for 20 to 28 hours, filtering the mixture by repeating 1 to 5 times, And the mixture is concentrated at a temperature of 1 to 20 占 폚.
삭제delete
삭제delete
삭제delete
삭제delete
삭제delete
상기 농축액은 후속하여 동결건조되어 추출분말로 제조될 수 있으며, 동결건조된 추출분말은 다시 70% 내지 90%(v/v)인 에탄올에 용해시켜 사용할 수 있다.The concentrate can be subsequently lyophilized to produce an extract powder, and the lyophilized extract powder can be used by dissolving in ethanol of 70 to 90% (v / v) again.
삭제delete
본 발명에 따르면, 무청 추출물의 항산화 활성을 가진 기능성 성분들이 염증으로 인해 발생하는 산화 스트레스를 줄이는 역할을 함으로써 궤양성 대장염증 발병시 동반되는 혈변 및 체중감소, 탈수 현상을 완화시킬 수 있는 무청 추출물을 포함하는 항염 및 항산화를 위한 조성물을 제공하는 효과가 있다.According to the present invention, functional ingredients having antioxidative activity of Wujing extract reduce the oxidative stress caused by inflammation, so that the extract of Wuchuan, which can reduce the blood, weight loss and dehydration accompanying the ulcerative colitis inflammation, And a composition for anti-inflammation and antioxidation.
도 1은 정상군, 대조군, 무청 급이군, 신선초 급이군에서의 변성세척겔에 전기영동하여 다양한 장내세균총을 확인한 전기영동 사진이다.
도 2는 결장 내 염증 세포의 외양을 나타내는 사진이다.FIG. 1 is an electrophoresis image showing various intestinal flora obtained by electrophoresis on denatured washing gels in normal group, control group, Wuqing class group, and Pseudomonas group.
2 is a photograph showing the appearance of inflammatory cells in the colon.
이하, 본 발명의 구체적인 실시예를 첨부한 도면을 참조하여 상세히 설명한다.Hereinafter, specific embodiments of the present invention will be described in detail with reference to the accompanying drawings.
본 발명은 무청 추출물을 유효활성 성분으로 포함함을 특징으로 하며, 특히 상기 무청 추출물은 무청을 탄소수 1 내지 4의 저급알코올로 이루어지는 군으로부터 선택되는 알코올, 바람직하게는 에탄올, 보다 바람직하게는 50 내지 90%(v/v) 에탄올, 가장 바람직하게는 70 내지 90%(v/v)인 에탄올을 추출용매로 사용하여 추출된 것일 수 있다. 특히, 상기 무청 추출물의 제조에 사용되는 무청은 무(Radish) 뿌리의 윗부분 즉, 줄기와 잎부분에 해당하는 것으로서, 주로 식용하는 무 뿌리를 제외하고 남는 부분이며, 엽록소가 넓게 분포되어 있고 당질 함량이 낮은 반면, 비타민 A, B1, B2, C, 나이아신, 단백질, 지질(脂質) 및 철분, 칼슘이 골고루 함유되어 있을 뿐 아니라, 풍부한 섬유질 식품으로 성인병 예방에도 좋은 것으로 알려져 있다. 상기 무청 추출물은 상기 무청을 수세, 건조, 바람직하게는 동결건조 후, 분쇄시켜 수득되는 건조분말을 추출용매, 바람직하게는 에탄올로 추출하여 수득되는 것일 수 있으며, 이때 동결건조 및 분쇄는 당업자에게는 용이하게 수행할 수 있을 정도로 공지된 것으로 이해될 수 있는 것으로서, 본 발명이 동결건조 및 분쇄의 방법이나 공정조건으로 제한되는 것은 아니다.In particular, the extract of Wuchuan is selected from the group consisting of alcohols selected from the group consisting of lower alcohols having 1 to 4 carbon atoms, preferably ethanol, more preferably 50 - , And 90% (v / v) ethanol, most preferably 70 to 90% (v / v) ethanol as an extraction solvent. Particularly, the mulberry extract used in the production of the extract of Wuchuan is a part of the upper part of radish root, that is, stem and leaf part, except for the radish root which is mainly used for cooking, and the chlorophyll is widely distributed, While it is low in vitamin A, B1, B2, C, niacin, protein, lipid, iron and calcium, and is rich in fiber foods. The Wuchung extract may be obtained by extracting the dried powder obtained by washing with water, drying, preferably lyophilization, and pulverization, with an extraction solvent, preferably ethanol. The freeze-drying and pulverization may be performed by a person skilled in the art The present invention is not limited to the method of lyophilization and pulverization or the processing conditions.
무청을 시래기로 만드는 기존의 방법으로는 무청이 가진 무기질 및 영양성분의 함량이 적고, 시료의 오염도가 큰 관계로 이를 방지하기 위해 건조방법인 동결건조를 통해 무청을 건조시켰다. 동결건조를 통해 건조한 시래기의 추출 및 농축 과정에서 가장 중요한 것은 온도이다. 추출 및 농축과정에서 열을 가하게 되면 무청이 가진 유용성분이 파괴되고, 남은 유용성분 잔존량 역시 적어진다. 따라서 본 실험에서는 농도가 결코 20℃ 이상으로 넘어가지 않도록 하여 추출된 유용성분의 변화 가능성을 줄였다. In order to prevent this problem, the conventional method of making a mushroom is to dry the mushroom through freeze - drying, which is a drying method, because the amount of minerals and nutrients contained in the mushrooms is small and the contamination degree of the sample is large. The temperature is the most important factor in the extraction and concentration of dried Sagae through lyophilization. When heat is applied during the extraction and concentration process, the usable component of the wheat germ is destroyed, and the amount of the remaining useful ingredient is also reduced. Therefore, in this experiment, the concentration never exceeded 20 ° C and the possibility of the change of the extracted useful ingredient was reduced.
본 발명에서 무청이라 함은 무 뿌리를 제외한 잎과 줄기를 생물 상태, 건조 상태 모두를 포함하는 것으로 의미하며, 달리 시래기 등과 같이 건조된 상태를 전제로 불리워지는 칭호 또한 포함하는 것으로 이해되어야 한다.In the present invention, the term " silken " means that leaves and roots other than rootless roots are included in both biological state and dry state, and it should be understood that the term " roots "
달리 시래기라고도 불리우는 무청, 특히 무청 건조물은 글리코나스투르티인(glyconasturtiin), 글리코시놀레이트(glycosinolate), 메틸머캅탄(methyl mercaptane)과 겨자유(mustard oil) 등의 항암성분은 물론 유해활성산소 소거능력이 밝혀진 베타-카로텐(-carotene), 안토시아닌(문헌 Malisorn C, Suntornsuk W. 2008. Improved -carotene production of Rhodotorula glutinis in fermented radish brine by continuous cultivation. Biochem Engineer J doi:10.1016/j.bej.2008.08.005 참조), 클로로필(문헌 Yu BP. 1996. Aging and antioxidative stress: Modulation by dietary restriction. Free Rad Biol Med 21: 651-668 참조), 비타민 C(문헌 Anatol K, Ulrike M, Sonke A, Amaar U, Charlotte L, Tomas MT, Ulrike B. 2001. Influence of vitamin E and C supplementation on lipoprotein oxidation in patients with Alzheimerdisease. Free Rad Biol Med 31: 345-354 참조)를 함유하고 있으며, 건물량 중 35% 이상이 식이섬유이고, 20% 내외의 단백질과 철분, 칼슘 등을 함유한 양질의 식재료이다(문헌 Ku KH, Lee KA, Kim YL, Lee YW. 2006. Quality characteristics of hot-air dried radish(Raphanus sativus L.) leaves. J Korean Soc Food Sci Nutr 34 : 780-550 참조).In addition to the anticancer components such as glyconasturtin, glycosinolate, methyl mercaptane and mustard oil, as well as anti-cancer components such as harmful active oxygen scavenging Beta-carotene, anthocyanin (Malisorn C, Suntornsuk W. 2008. Improved-carotene production of Rhodotorula glutinis in fermented radish brine by continuous cultivation, Biochem Engineer J doi: 10.1016 / j.bej.2008.08. 005), chlorophyll (see Yu BP, 1996. Aging and antioxidative stress: Modulation by dietary restriction, Free Rad Biol Med 21: 651-668), vitamin C (literature Anatol K, Ulrike M, Sonke A, In the present study, we found that more than 35% of the dry matter was found in the dietary intake of Alzheimer's disease (Alzheimer's disease, Free Rad Biol Med 31: 345-354) Fiber, and 2 It is a good quality food containing 0% protein, iron, calcium, etc. (Ku KH, Lee KA, Kim YL, Lee YW 2006. Quality characteristics of hot-air dried radish (Raphanus sativus L.) leaves. Korean Soc Food Sci Nutr 34: 780-550).
관련 연구로는 조리방법에 따른 상용채소의 무기질 함량 변화(문헌 Han JS, Kim JS, Kim MS, Choi YH. 1999. Changes on mineral contents of vegetable by various cooking methods. Korean J Soc Food Sci 15 : 382-387 참조), 사료로 사용하기 위한 무청에서의 단백질 추출(문헌 Yasui T. 1996. Effect of the pretreatment with dilute hydrochloric acid solutions on the extractability of grass proteins. Nippon Eiyo Shokuryo Gakkaishi 49: 29-37; Yasui T. 1995. Method for extraction of grass proteins by dilute-alkaline acetone solution. Nippon Eiyo Shokuryo Gakkaishi 48: 391-397 참조)에 관한 것이 있으며, 그 밖에도 시래기 에탄올 추출물이 폐암에 미치는 영향(문헌 Yim HB, Lee GS, Chae HJ. 2004. Cytotoxicity of ethanol extract of Raphanuse sativus on a human lung cancer cell line. J Korean Soc Food Sci Nutr 33: 287-290 참조), 시래기 추출물의 위장 내 자극과 자궁 수축 활성능(문헌 Ghayur MN, Gilani AH. 2005. Gastrointestinal stimulatory and uterotonic activities of dietary radish leaves extract are mediated through multiple pathways. Phytother Res 19: 750-755 참조), 장내 자극 변화(문헌 Gilani AH, Ghayur MN. 2004. Pharmacological basis for the gut stimulatory activity of Raphanus sativus leaves. J Ethnopharmacol 95: 169-172 참조) 및 생리활성(문헌 Ku KH, Lee KA, Kim YE. 2008. Physiological Activity of Extracts from Radish (Raphanus sativus L.) Leaves. J Korean Soc Food Sci Nutr 37(3) : 390-395 참조)에 관한 연구결과가 보고되었다. 그 외에도 시래기 분말의 항고혈압효과(문헌 Kim BR, Park JH, Kim SH, Cho KJ, Chang MJ. 2010. Antihypertensive Properties of Dried Radish Leaves Powder in Spontaneously Hypertensive Rats. Korean J Nutr 43(6): 561~ 569 참조)와 콜레스테롤 식이를 공급한 흰쥐의 간(문헌 Rhee SJ, Ahn JM, Ku KH, Choi JH. 2005. Effects of Radish Leaves Powder on Hepatic Antioxidative System in Rats Fed HighCholesterol Diet. J Korean Soc Food Sci Nutr 34(8) : 1157-1163 참조) 및 장기능과 지질대사 개선(문헌 Jang HS, Ahn JM, Ku KH, Rhee SJ, Kang SK, Choi JH. 2008. Effect of Radish Leaves Powder on the Gastrointestinal Function and Fecal Triglyceride and Sterol Excretion in Rats Fed a Hypercholesterolemic Diet. J Korean Soc Food Sci Nutr 37(10) : 1258-1263 참조)에 대한 연구가 진행되었다. 그러나 직접적인 대장염증과 관련한 연구는 미비하였다.The results of this study are as follows: 1) Changes in mineral content of commercial vegetables according to cooking methods (Han, JS, Kim, MS, Choi, YH 1999. Changes in minerals contents of vegetable by various cooking methods. Korean J Soc Food Sci 15: 382- 387), protein extraction from aquaculture for use as feed (Yasui T. 1996. Effect of the pretreatment with dilute hydrochloric acid solutions on the extractability of grass proteins. Nippon Eiyo Shokuryo Gakkaishi 49: 29-37; Yasui T. et al. (See, for example, Yim HB, Lee GS, Chae et al., 1995), and the effect of ethanol extract of Seagrass on lung cancer HJ. 2004. Cytotoxicity of ethanol extracts of Raphanus sativus on a human lung cancer cell line, J Korean Soc Food Sci Nutr 33: 287-290), the gastrointestinal stimulation of uterus extract and the uterine contraction activity (Ghayur MN, Gilani AH 2005. Ga (Gilani AH, Ghayur MN, 2004. Pharmacological basis for the gut stimulatory activity of Raphanus sativus leaves. . J Ethnopharmacol 95: 169-172) and physiological activity (Ku KH, Lee KA, Kim YE. 2008. Physiological Activity of Extracts from Radish (Raphanus sativus L.) Leaves. J Korean Soc Food Sci Nutr 37 390-395) have been reported. In addition, antihypertensive effects of Sira powder (Kim BR, Park JH, Kim SH, Cho KJ, Chang MJ. 2010. Antihypertensive Properties of Dried Radish Leaves Powder in Spontaneously Hypertensive Rats. J Nutr 43 (6): 561 ~ 569 ) And cholesterol diet-fed rats (Rhee SJ, Ahn JM, Ku KH, Choi JH, 2005. Effects of Radish Leaves Powder on Hepatic Antioxidative System in Rats Fed High Cholesterol Diet. J Korean Soc Food Sci Nutr 34 8): 1157-1163) and improvement of bowel function and lipid metabolism (Jang HS, Ahn JM, Ku KH, Rhee SJ, Kang SK, Choi JH 2008. Effect of Radish Leaves Powder on Gastrointestinal Function and Fecal Triglyceride Sterol Excretion in Rats Fed a Hypercholesterolemic Diet. J Korean Soc Food Sci Nutr 37 (10): 1258-1263). However, there have been few studies on direct colonic inflammation.
상기 무청 추출물은 무청을 추출하여 제조되며, 이때 추출비율은 무청의 70% 내지 90%(v/v)인 에탄올 90 내지 99중량% 및 상기 무청의 건조분말 1 내지 10중량%의 비율로 혼합하고, 상온에서 40 내지 54시간 동안 현탁시킨 후, 다시 20 내지 28시간 동안 침지시킨 후, 여과하는 과정을 1 내지 5번 반복하여 얻은 추출물을 합하여 1 내지 20℃의 온도조건에서 농축시킨 것일 수 있다.The extract of Wuchuan is prepared by extracting the extracts with a ratio of 90 to 99% by weight of ethanol with 70% to 90% (v / v) of the extract and 1 to 10% , Suspending the mixture at room temperature for 40 to 54 hours, immersing again for 20 to 28 hours, filtering the mixture 1 to 5 times, and concentrating the extracts at a temperature of 1 to 20 ° C.
상기 수득된 농축액은 후속하여 동결건조하여 추출분말로 제조될 수 있다.The concentrate thus obtained may be subsequently freeze-dried to produce an extract powder.
상기 동결건조된 추출분말은 다시 70% 내지 90%(v/v)인 에탄올에 용해시켜 사용할 수 있다.The lyophilized extract powder can be used again by dissolving in 70% to 90% (v / v) ethanol.
상기 무청 추출물은 동결건조시켜 과립형의 식이 분말로 만들어질 수 있다.The Wuchuan extract may be lyophilized to make a granular dietary powder.
이하에서 본 발명의 바람직한 실시예 및 비교예들이 기술되어질 것이다.Hereinafter, preferred embodiments and comparative examples of the present invention will be described.
이하의 실시예들은 본 발명을 예증하기 위한 것으로서 본 발명의 범위를 국한시키는 것으로 이해되어져서는 안될 것이다.The following examples are intended to illustrate the invention and should not be construed as limiting the scope of the invention.
1.추출물 및 식이 분말 조제1. Preparation of extract and dietary powder
1)무청 추출물 조제1) Preparing wuchu extract
일반 마트에서 구입한 국내산 무청은 오염도 및 영양성분의 파괴를 막기 위해 흐르는 물로 깨끗이 세척한 후, 동결건조 한 다음, 믹서기로 분쇄하여 입자형태의 건조분말로 만든 후, 80%(v/v)에탄올(EtOH)을 용매로 농도 5%가 되도록 하여 무청 추출물을 제조하였다. 이때, 보다 구체적으로는 80%(v/v)에탄올 95중량%에 무청 건조분말 5중량%를 혼합하고, 48시간 동안 상온에서 현탁시킨 후, 다시 24시간 동안 방치시켜 침지시킨 후, 여과하였다. 이 과정을 3회 반복하여 수득된 추출물을 모아 20℃ 이하의 온도조건에서 감압 농축기로 농축시켰다. 수득된 농축액을 동결건조하여 추출분말(고형분)로 만든 것을 저장하고, 후속하는 실험에 사용하였다.In order to prevent the destruction of pollutants and nutrients, the domestic aquaculture purchased from general marts was thoroughly washed with running water, lyophilized, and then pulverized with a blender to obtain a dry powder in the form of particles. Then, 80% (v / v) (EtOH) as a solvent to a concentration of 5%. At this time, more specifically, 5% by weight of non-woven dry powder was mixed with 95% by weight of 80% (v / v) ethanol, suspended at room temperature for 48 hours, allowed to stand for another 24 hours and then filtered. This process was repeated three times, and the obtained extracts were collected and concentrated under reduced pressure at a temperature of 20 DEG C or less. The obtained concentrate was freeze-dried to obtain an extract powder (solid), which was used in the subsequent experiments.
상기 동결건조된 추출분말 형태의 무청 추출물을 에탄올에 중량비로 1 : 19의 비율(파우더를 액체에 용해시킬 때 사용하는 단위로 무청 파우더 1중량부 : 99.9%(v/v)에탄올 19중량부)비율로 용해시켜 항산화 활성 실험에 사용하였다.The lyophilized extract powder of the freeze-dried extract powder was dissolved in ethanol at a ratio of 1: 19 (19 parts by weight of 99.9% (v / v) ethanol as a unit used to dissolve the powder in the liquid) , And used for the antioxidant activity test.
상기 동결건조된 추출분말 형태의 무청 추출물을 분말화하여 동물 실험에서의 식이 분말로 사용하였다.The lyophilized extract powder of the lyophilized extract powder was pulverized and used as a dietary powder in an animal experiment.
2)무청 추출물을 포함하는 과립형의 식이 분말의 실험동물 급이2) Experimental animal feed of granular dietary powder containing Wujing extract
3주령 된 ICR(imprinting control regions) 생쥐 54마리를 정상군(Normal), 염증 유발군, 염증유발 식이 분말 급이군으로 나누어 사료를 제공하여 생육시켰다. 그 처방을 하기 표 1에 요약하였다. 실험동물은 습도 50%, 온도 25℃의 조절된 환경조건에서 사육하였으며, 명암주기는 12시간 주기로 조절하였다.Fifty - four week old three - week - old imprinting control regions (ICR) mice were divided into normal, irritated, and inflammatory feed groups. The prescription is summarized in Table 1 below. Experimental animals were maintained under controlled environmental conditions of 50% humidity and 25 ℃.
* DN : 염증유발군(AIN-93G 사료 + DSS로의 염증 유발)
* DV : 염증유발 식이 분말 급이군(AIN-93G 사료 + 분말 식이 + DSS로의 염증 유발)
단위 : 중량%* N: Normal group
* DN: inflammation-inducing group (inflammation induced by AIN-93G feed + DSS)
* DV: Inflammation-induced dietary powder (AIN-93G feed + powdered diet + inflammation induced by DSS)
Unit: wt%
3)실험 동물 및 사육 조건3) Experimental animals and breeding conditions
3주령 된 ICR 생쥐 54마리를 정상군, 염증유발군, 염증유발 식이 분말 급이군으로 나누어 AIN-93G사료를 제공하되, 염증유발 식이 분말 급이군에는 각각의 상기 식이 분말을 5%의 비율로 혼합하여 만든 사료를 제공하였다. 제조방법은 상기 표 1에 기재하였으며, 실험동물은 습도 50%, 온도 25℃의 조절된 환경조건에서 사육하였으며 명암주기는 12시간 주기로 조절하였다. Seventy-four week old ICR mice were divided into normal group, inflammation induction group and inflammation induction group, and AIN-93G feed was provided. In the inflammatory induction powder group, each of the above dietary powders was mixed at a ratio of 5% To provide feeds. The preparation method is shown in Table 1, and the experimental animals were bred at a controlled humidity of 50% at a temperature of 25 ° C, and the light-dark cycle was adjusted at a cycle of 12 hours.
4)실험 일정 및 대장염 유발 방법4) Schedule of experiment and induction of colitis
실험기간은 총 5주로, 4주간의 대장염증 비-유발기간과 5일의 대장염증 유발기간으로 나누어 진행하였으며, 후쿠다(Fukata) 등의 방법에 따라 생쥐에 3%의 DSS(Dextran sulfate sodium, 분자량 36,000 내지 50,000달톤(Da))를 섭취시켜 대장염을 유발시켰다. The duration of the experiment was divided into 5 weeks of total, 4 weeks of non-inflammatory period of colonic inflammation and 5 days of colon inflammation induction period. According to the method of Fukata et al., 3% of Dextran sulfate sodium (molecular weight 36,000 to 50,000 daltons (Da)) to induce colitis.
5일간 정상군을 제외한 모든 군에게 3% DSS가 포함된 음용수를 섭취하게 한 이유는 대식세포 때문으로, 대식세포는 고유판과 점막하층 전체에 균일하게 분포하지만 DSS에 노출된 6일째부터 염증이 침윤된 장소에 대식세포의 수가 증가하므로 염증으로 인한 대장 손상정도를 가장 정확하게 파악하기 위해 5일 동안 염증을 유발시켰다. For 5 days, all groups except the normal group were fed with drinking water containing 3% DSS because of macrophages, and macrophages were uniformly distributed throughout the intrinsic plate and submucosal layer, but inflammation from the 6th day after exposure to DSS The number of macrophages increased in the infiltrated area, so inflammation was induced for 5 days in order to obtain the best accuracy of inflammation - induced colon damage.
5)체중 증가량, 식이 및 음용수 섭취량 측정5) Measurement of weight gain, dietary and drinking water intake
체중 증가량과 식이 및 음용수 섭취량은 염증유발 전에는 매주 1회 측정하였으며, 염증 후에는 매일 측정하였다. 이를 토대로 개체군별 식이효율과 DSS 섭취량을 하기 수학식 1에 의하여 산출하였다. 또한 3% DSS로 대장염을 유도하는 5일 동안 매일 수거하여 혈변수와 무게를 측정하였다.Weight gain, dietary and drinking water intake were measured once a week before inflammation induction and daily after inflammation. Based on this, the dietary efficiency and DSS intake by population were calculated by the following equation (1). Blood counts and weights were also collected daily for 5 days during which colitis was induced by 3% DSS.
[수학식1][Equation 1]
식이 효율(Food Efficiency Ratio) = 체중 증가량(g/일)/식이섭취량(g/일)Food Efficiency Ratio = Weight gain (g / day) / Dietary intake (g / day)
DSS 부하(load) = (총 음용량(㎖) * DSS 농도(㎎/㎖)) / 초기 체중(g)DSS load = (total negative volume (ml) * DSS concentration (mg / ml)) / initial weight (g)
6)희생 및 시료수집6) Sacrifice and sample collection
①대장 길이 측정① Measure length of colon
실험동물은 희생 전날 12시간 금식한 후, 이산화탄소(CO2)로 마취 후, 개복하여 대장 부위 중 맹장(cecum)부터 항문(anus) 직전 부위까지의 대장을 적출하였다. 적출한 장기는 생리식염수에 세척하여 혈액과 지방을 제거하고 흡습지로 수분을 빨아들인 후, 길이를 측정하였다.The animals were fasted for 12 hours on the day before sacrifice and then anesthetized with carbon dioxide (CO 2 ), and then the colon was removed from the cecum to the anus immediately before the anus. The extracted organs were washed with physiological saline to remove blood and fat, and the water was sucked into the absorbent paper and then the length was measured.
②대장염의 조직학적 평가 ② Histological evaluation of colitis
중성 포르말린에 고정한 대장조직을 48시간 내에 근위부, 중간부, 원위부를 한 조각씩 취하여 일반적인 조직처리과정을 거쳐 파라핀에 포매한 후, 5 내지 6의 두께로 절편을 만들었으며, 헤마톡실린 앤드 에오신(Hematoxylin & Eosin) 용액으로 염색 후, 궤양 유무 및 염증 정도를 점수의 합계로 계산하였다.The colon tissue fixed to the neutral formalin was taken into the paraffin through a general tissue treatment process after taking one piece of the proximal, middle, and distal portions within 48 hours, and the section was cut to a thickness of 5 to 6. Hematoxylin and eosin Hematoxylin & Eosin) solution, and the degree of ulceration and inflammation were calculated as the sum of the scores.
③ 판독기준③ Reading standard
DSS에 의하여 유도된 대장 염증의 소견은 유안(Yuan)의 기준(표 2)에 따라 판독하여 점수화하였다. 점수화는 각 개체별로 3곳의 절편에서 판독한 점수를 모두 합한 값에 대하여 각 군별로 평균과 표준편차로 표시하였으며, 6단계로 염증의 정도를 나누었다.The findings of DSS-induced colonic inflammation were read and scored according to Yuan's criteria (Table 2). Scores were expressed as the mean and standard deviation for each group, and the degree of inflammation was divided into 6 groups.
7)대장염 유발 동물의 장내 미생물 변화 비교 7) Comparison of intestinal microbial changes in colitis induced animals
대조군과 상기 식이 분말 급이군을 구분하여 동물실험 수행 후, 대장 조직 적출하여 3 내지 5㎛ 정도의 쌀알크기로 절편한 후, 조직용 DNA 미니프렙 킷트(DNA miniprep kit for tissue: 미합중국 소재 키아젠사(Quiagen co.)와 QIAcube(미합중국 키아젠사)를 사용하여 DNA를 분리한 후, 338f-GC와 518r 프라이머쌍(primer pair)으로 박테리아 유전자 DNA(bacterial genomic DNA) 중 16S rDNA 유전자만을 증폭하여 변성세척겔(denaturing detergent gel)에 전기영동하여 장내 미생물 패턴 분석하였다. The control group and the dietary powder-fed group were separated and subjected to animal experiments. The colon tissues were extracted and sectioned into a rice grain size of about 3 to 5 쨉 m. Then, a DNA miniprep kit for tissue (manufactured by Kia Motors Corporation DNA was isolated using Qi cube (Qiagen Co.) and QIAcube (Kia Kogen Co., USA), amplified only 16S rDNA gene of bacterial genomic DNA with 338f-GC and 518r primer pair, (denaturing detergent gel) to analyze intestinal microbial patterns.
2.항산화 성분2. Antioxidant component
1)총 폴리페놀 함량 1) Total polyphenol content
상기 무청 추출물 200㎕에 2% Na2CO3 2㎖을 넣어 섞어준 다음, 1M FC 시약(50% 폴린-시오칼토 페놀 시약(Folin-ciocalteu's phenol regent), 2N 100㎎/㎖ in 1차 증류수(1st distilled water))(미합중국 소재 시그마사(Sigma Co.) 200㎕를 첨가하여 실온에서 30분 동안 반응시키고, 750㎚에서 흡광도를 측정하였다. 대조군으로는 탄닌산(Tannin acid: 미합중국 시그마사)을 사용하였으며, 검량선은 하기 수학식 2를 통해 산출하였다. 2 μl of 2% Na 2 CO 3 was added to 200 μl of the Wuchung extract and mixed with 1M FC reagent (50% Folin-ciocalteu's phenol regent, 2N 100 mg / ml in primary distilled water (Distilled water)) (200 mu l of Sigma Co., USA) was added and reacted at room temperature for 30 minutes, and absorbance was measured at 750 nm. Tannin acid (Sigma Co., USA) was used as a control group And the calibration curve was calculated by the following equation (2).
[수학식2]&Quot; (2) "
검량선 공식 : Y = aX+bCalibration curve formula: Y = aX + b
여기에서, X는 시료액의 농도별 흡광도 값이고, Y는 시료액의 농도이고, a는 기울기이고, b는 절편이며, 이들 a 및 b는 샘플 스톡 용액(sample stock solution)의 단계별 농도(X)에 대한 억제 농도(inhibition concentration) (Y)에 대해 작성된 방정식으로부터 얻었다. 시료 중 총 폴리페놀 함량은 하기 수학식 3을 통해 산출하였다.Where a is the slope and b is the intercept. These a and b are the concentration of the sample stock solution (X ) From the equation created for the inhibition concentration (Y). The total polyphenol content in the samples was calculated by the following equation (3).
[수학식3]&Quot; (3) "
시료 중 총 폴리페놀 함량 = Y * V/STotal polyphenol content in the sample = Y * V / S
상기 식에서, Y는 시료의 흡광도 값을 검량선에 대입하여 얻은 Y값이고, V는 시료 추출액의 조제단계에서 사용된 추출용매의 부피이고, 그리고 S는 추출시료의 무게이다.Y is the Y value obtained by substituting the absorbance value of the sample into the calibration curve, V is the volume of the extraction solvent used in the preparation of the sample extract, and S is the weight of the extracted sample.
2)총 플라보노이드 함량2) Total flavonoid content
상기 무청 추출물 1㎖에 디에틸렌글리콜(Diethylenglycol) 10㎖을 넣어 섞어준 다음, 1N 수산화나트륨(NaOH) 1㎖을 첨가하여 상온에서 1시간 반응 후, 분광광도계로 420㎚에서 흡광도를 측정하였다. 대조군으로 갈산(gallic acid: 미합중국 소재 시그마사)을 사용하였다. 검량선 공식은 하기 수학식 4에 나타내었다.10 ml of diethylenglycol was added to 1 ml of the extract and 1 ml of 1 N sodium hydroxide (NaOH) was added. After reacting at room temperature for 1 hour, the absorbance was measured with a spectrophotometer at 420 nm. Gallic acid (Sigma, USA) was used as a control. The calibration curve formula is shown in Equation 4 below.
[수학식4]&Quot; (4) "
검량선 공식 : Y = aX+bCalibration curve formula: Y = aX + b
상기 식에서, X는 시료액의 농도별 흡광도 값이고, Y는 시료액의 농도이고, a는 기울기이고, b는 절편이며, 이들 a 및 b는 샘플 스톡 용액의 단계별 농도(X)에 대한 억제 농도 (Y)에 대해 작성된 방정식으로부터 얻었다.Where a is the slope and b is the intercept, these a and b are the inhibition concentrations for the stepwise concentration (X) of the sample stock solution, and X is the absorbance value for each concentration of the sample liquid, Y is the concentration of the sample liquid, (Y). ≪ / RTI >
시료 중 총 플라보노이드 함량은 하기 수학식 5를 통해 산출하였다.The total flavonoid content in the sample was calculated by the following equation (5).
[수학식 5]&Quot; (5) "
시료 중 총 플라보노이드 함량 = Y * V/STotal flavonoid content in the sample = Y * V / S
상기 식에서, Y는 시료의 흡광도 값을 검량선에 대입하여 얻은 Y 값이고, V는 무청 추출물의 조제단계에서 사용된 추출용매의 부피이고, 그리고 S는 추출시료의 무게이다.Where Y is the Y value obtained by substituting the absorbance value of the sample into the calibration curve, V is the volume of the extraction solvent used in the step of preparing the Wuchuan extract, and S is the weight of the extracted sample.
2)항산화 활성2) Antioxidant activity
(1)전자 공여능 (1) Electronic Difficulty
전자공여능(Electron Donating Ability : EDA)은 시료에 대한 DPPH(1,1-디페닐-2-피크리드라질(1,1-diphenyl-2-picrydrazyl))의 전자공여 효과로 시료의 환원력을 측정하는 방법으로 추(Chu)의 방법을 변형하여 측정하였다(문헌 Chu SM. 2007. Antioxidative and antimicrobial activities of medicinal plants collected from Nepal. Dankook University. Master's thesis를 참조하시오). 농도별 희석한 무청 추출물을 96웰 플레이트(96 well plate)의 각 웰에 100㎕씩 분주하고, 다시 여기에 150μM DPPH(메탄올(MeOH) 중의 59.145㎎/㎖: 미합중국 소재 시그마사)용액 150㎕를 첨가하여 섞은 다음, 실온에서 30분간 반응시키고 518㎚에서 흡광도를 측정하였다. 대조군으로는 아스코르빈산(Ascorbic acid: 미합중국 소재 시그마사)를 사용하였다. 억제 농도는 하기 수학식 6을 통해 산출하였다.Electron donating ability (EDA) is measured by the electron donating effect of DPPH (1,1-diphenyl-2-picrydrazyl) on the sample. (Chu SM, 2007. Antioxidative and antimicrobial activities of medicinal plants collected from Nepal, Dankook University, Master's thesis). 100 μl of each of the wells of the 96-well plate diluted with the concentration was diluted, and 150 μl of a solution of 150 μM DPPH (59.145 mg / ml in methanol (MeOH): Sigma Co., USA) And the mixture was reacted at room temperature for 30 minutes, and absorbance was measured at 518 nm. Ascorbic acid (Sigma, USA) was used as a control. The inhibitory concentration was calculated by the following equation (6).
[수학식 6]&Quot; (6) "
억제 농도(%) = (1-D/C) * 100Inhibitory concentration (%) = (1-D / C) * 100
Y = aX+bY = aX + b
IC50 = (0.5-b)/aIC 50 = (0.5-b) / a
상기 식에서, D는 무청 추출물 첨가구의 흡광도이고, C는 블랭크(blank) 흡광도이고, a는 기울기이고, b는 절편이며, 이들 a 및 b는 샘플 스톡 용액의 단계별 농도(X)에 대한 억제 농도 (Y)에 대해 작성된 방정식으로부터 얻었다. IC50은 유리 라디칼(free radical)의 활성을 50%로 저해하는데 필요한 농도이다.Where a is the slope and b is the intercept, these a and b are the inhibitory concentrations (X) for the stepwise concentration (X) of the sample stock solution, D is the absorbance of the Wuchsia extract solution, C is the blank absorbance, Y). ≪ / RTI > IC 50 is the concentration required to inhibit the activity of free radicals by 50%.
(2)과산화물 제거효소(SOD: Superoxide dismutase) 유사 활성(2) Superoxide dismutase (SOD) -like activity
SOD 유사활성은 마크룬드(Marklund) 등의 방법을 변형하여 측정하였다(문헌 Marklund S and Marklund G. 1974. Involvement of superoxide anon radical in the oxidaton of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem 47 : 468을 참조하시오). 상기 무청 추출물 20㎕에 희석용 완충제(Dilution Buffer)와 효소 작업용액(Enzyme Working solution)을 20㎕씩 넣어준 후, 상온에서 20분간 반응시킨 후, 450㎚에서 흡광도를 측정하였다. 블랭크는 시료 대신 3차 증류수를 넣어주었으며, SOD 활성 억제율(SOD activity inhibition rate)을 계산하는 계산식은 하기 수학식 7을 통해 구하였다.SOD-like activity was measured by modification of the method of Marklund et al. (Marklund S and Marklund G. 1974. Involvement of superoxide anion radicals in pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem 47: 468). Dilution buffer (Dilution Buffer) and Enzyme Working Solution (20 μl) were added to 20 μl of the Wuchung Extract, and reacted at room temperature for 20 minutes. Absorbance was measured at 450 nm. Blank was added to the third distilled water instead of the sample, and a calculation formula for calculating the SOD activity inhibition rate was obtained by the following equation (7).
[수학식7]&Quot; (7) "
SOD 활성 억제율 = [(블랭크1-블랭크3) - (샘플-블랭크2)] / (블랭크1-블랭크3) * 100SOD activity inhibition rate = [(Blank 1 - Blank 3) - (Sample - Blank 2)] / (Blank 1 - Blank 3) * 100
상기 식에서, 블랭크1은 3차 증류수 + WST-1 작업용액(2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfo-phenyl)-2H-tetrazolium monosodium salt) + 효소 작업용액이고, 블랭크2는 샘플용액(대조군으로 사용할 물질) + WST-1 작업용액(2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfo-phenyl)-2H-tetrazolium monosodium salt) + 희석용 완충제이고, 그리고 블랭크3은 WST-1 작업용액(2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfo-phenyl)-2H-tetrazolium monosodium salt) + 희석용 완충제이다.In the above equation, Blank 1 is a mixture of tertiary distilled water + 2- (4-iodophenyl) -3- (4-nitrophenyl) -5- (2,4- disulfo-phenyl) -2H- tetrazolium monosodium salt + Enzyme working solution and Blank 2 is a sample solution (a substance to be used as a control) + 2- (4-iodophenyl) -3- (4-nitrophenyl) -5- ) -2H-tetrazolium monosodium salt + diluting buffer, and Blank 3 is a solution of 2- (4-iodophenyl) -3- (4-nitrophenyl) -5- ) -2H-tetrazolium monosodium salt) + diluent buffer.
(3) ABTS + 라디칼 소거활성(3) ABTS + radical scavenging activity
상기 식이 분말에 대한 ABTS(2,2'-아지노비스-(3-에틸벤즈티아졸린-6-설폰산)(2,2'-azinobis-(3-ethylbenzthiazoline-6-sulphonic acid)) 라디칼 소거활성은 반덴버그(Van den Berg) 등의 방법을 변형하여 측정하였다(문헌 Van den Berg R, Haenen GR, Van den Berg H. Bast A. 1999. Applicability of an improved Trolox equivalent antioxidant capacity(TEAC) assay for evaluation of antioxidant capacity measurements of mixtures. Food Chem 66 : 511-517을 참조하시오). 7.4mM의 ABTS 시약과 2.6mM 과황산칼륨(potassium persulfate)을 3차 증류수에 녹인 후, 14시간 동안 암소 속에서 반응 및 안정화시킨 다음, 50배 희석하여 735㎚에서 흡광도를 측정하였을 때 흡광도 값이 1.4 내지 1.5 사이로 나오도록 하였다. 시료 10㎕와 ABTS 시약 200㎕를 혼합한 후, 상온에서 30분간 반응시켰으며, 대조군으로는 아스코르빈산을 사용하였다. ABTS 라디칼 소거능은 하기 수학식 8을 통해 산출하였다.The ABTS (2,2'-azinobis- (3-ethylbenzthiazoline-6-sulphonic acid)) radical scavenging activity of the dietary powder (2,2'-azinobis- (Van den Berg, Haenen GR, Van den Berg H. Bast A. 1999. Applicability of an improved trolox equivalent antioxidant capacity (TEAC) assay for evaluation 7.4 mM ABTS reagent and 2.6 mM potassium persulfate were dissolved in tertiary distilled water and reacted and stabilized in the dark for 14 hours. , And the absorbance was measured at 735 nm at a dilution of 50 × to obtain an absorbance value of between 1.4 and 1.5. After mixing 10 μl of the sample and 200 μl of the ABTS reagent, the mixture was allowed to react at room temperature for 30 minutes, The ABTS radical scavenging activity was measured by the following equation It is calculated through Equation 8.
[수학식8]&Quot; (8) "
ABTS 라디칼 소거능 (%) = ((블랭크 광학밀도 - 샘플 광학밀도) / 블랭크 광학밀도) * 100ABTS radical scavenging ability (%) = ((blank optical density-sample optical density) / blank optical density) * 100
상기 식에서, 블랭크 광학밀도(blank O.D)는 아스코르빈산 + ABTS 시약의 흡광도 값이다.In this equation, the blank optical density (blank OD) is the absorbance value of the ascorbic acid + ABTS reagent.
3.통계분석3. Statistical Analysis
실험결과는 SAS(Satistic Analysis System)을 이용하여 통계처리 하였으며, 평균표준편차(Mean)를 구하였다. 실험군 간의 평균값의 차이를 검증하기 위하여 일원배치 분산분석(one-way analysis of variance)를 한 후, 던칸 다중검정(Duncanmultiple range test)으로 변인간의 차이를 검증하였다. 모든 통계적인 유의성은 0.05 미만인 수준에서 실시하였다. 또한 총 폴리페놀, 총 플라보노이드 함량과 항산화 활성과의 연관성은 선형회귀분석을 실시하여 검토하였다.The results were statistically analyzed using SAS (Satisical Analysis System) and the mean standard deviation was obtained. One-way analysis of variance was performed to test the difference between the mean values among the experimental groups, and the difference between the variables was verified by Duncanmultiple range test. All statistical significance was performed at a level of less than 0.05. The relationship between total polyphenol, total flavonoid content and antioxidant activity was examined by linear regression analysis.
4.결과 4. Results
1)무청 추출물의 항산화 활성 검정1) Antioxidant activity test of Wuchung extract
(1)전자 공여능(1) Electronic Difficulty
본 발명에 따른 무청 추출물의 IC50값은 대조군으로 사용된 비타민 C(아스코르빈산)에 비해 높은 것으로 확인되었다(표3 참조). 특히, 비슷한 계통의 열무가 5608.1㎍/㎖란 것을 감안하면, 일반 채소로서는 상당히 높다(문헌 Lim HW, Yoon JH, Kim YS, Lee MW, Park SY, Choi HK. 2007. Free radical scavenging and inhibition of nitric oxide production by four grades of pine mushroom(Tricholoma matsutake Sing.). Food Chem 103 : 1337-1342 참조). 이러한 결과가 나온 것은 무청에 함유된 총 폴리페놀의 함량이 식용으로 사용되는 채소들 중에서 많기 때문이다.The IC 50 value of the extract of Wuchuan according to the present invention was found to be higher than that of vitamin C (ascorbic acid) used as a control (see Table 3). In particular, considering that the heat of the similar system is 5608.1 μg / ml, it is quite high as a general vegetable (see Lim HW, Yoon JH, Kim YS, Lee MW, Park SY, Choi HK 2007. Free radical scavenging and inhibition of nitric oxide production by four grades of pine mushroom (Tricholoma matsutake Sing.), Food Chem 103: 1337-1342). This result is due to the fact that the total polyphenol content in the wheat germ is among the vegetables used for food.
선행 연구를 통해 총 폴리페놀 함량에 비례하여 DPPH 라디칼 소거능이 달라진다는 것은 널리 알려져 있다(문헌 Kim OK, Lee MW, Park WB, Ham SS, Kung SS. 1992. The Nutritional Components of Aerial Whole Plant and Juice of Angelica keiskei Koidz. Kor J Food Sci Technol 24(6) : 592-596) 따라서 무청 추출물의 DPPH 라디칼 소거능의 높은 활성에는 폴리페놀 함량과 관계에 있다.It is well known that DPPH radical scavenging ability is changed in proportion to the total polyphenol content through previous studies (Kim OK, Lee MW, Park WB, Ham SS, Kung SS 1992. The Nutritional Components of Aerial Whole Plant and Juice of Therefore, the high activity of DPPH radical scavenging ability of Wakun extract is related to polyphenol content.
2) 던칸 다중검정에 의한 그룹들 간의 유의적인 차이(p<0.05) 확인
3) IC: 억제활성은 농도-억제 곡선의 외삽에 의하여 수득된 3중 실험들의 50% 억제 농도의 평균으로 표현됨.1) Each value is expressed as the mean standard deviation of triplicate experiments.
2) Significant difference between groups by Duncan multiple test (p <0.05).
3) IC: The inhibitory activity is expressed as the mean of the 50% inhibitory concentration of triplicates obtained by extrapolation of the concentration-inhibition curve.
(2) 총 폴리페놀 함량 (2) Total polyphenol content
본 발명에 따른 무청 추출물의 총 폴리페놀 함량은 2.84g/100g으로 나왔다(표 4 참조). 선행연구에서(문헌 Jin SY. 2011. Study on Antioxidant Activities of Extracts from Different Parts of Korean and Iranian Pomegranates. J Korean Soc Food Sci Nutr 40(8) : 1063-1072 참조), 상용채소인 브로콜리, 시금치, 양파, 감자, 오이의 총 페놀함량과(80.8 1.2, 79.6 8.4, 68.9 1.8, 23.3 5.8, 14.4 1.5 mg/100g) 비교하였을 때, 많은 양의 폴리페놀이 무청 추출물에 함유되어 있는 것을 알 수 있다. The total polyphenol content of the Wako extract according to the present invention was found to be 2.84 g / 100 g (see Table 4). In a previous study (see Jin SY, 2011. Study on Antioxidant Activities of Extracts from Different Parts of Korean and Iranian Pomegranates, J Korean Soc Food Sci Nutr 40 (8): 1063-1072), commercial vegetables such as broccoli, spinach, (80.8 1.2, 79.6 8.4, 68.9 1.8, 23.3 5.8, 14.4 1.5 mg / 100g) of potato and cucumber were found to contain a large amount of polyphenols.
(Tannin acid)Tannic acid
(Tannin acid)
2) 던칸 다중검정에 의한 그룹들 간의 유의적인 차이(p<0.05) 확인1) Each value is expressed as the mean ± standard deviation of triplicate experiments.
2) Significant difference between groups by Duncan multiple test (p <0.05).
(3) 총 플라보노이드 함량 측정(3) Measurement of total flavonoid content
플라보노이드(flavonoid)는 많은 염증관련 연구들에서 부작용 없는 염증 치료제로서의 가능성을 가지고 있는 것으로 확인되었는데, 특히 LPS로 자극된 쥐의 섬유모세포에서 NF-kB의 활성 및 장 상피세포인 IEC18 세포와 골수 수지상 세포에서 IkB 키나아제 활성 및 TNF- 분비가 억제하며, 크론병 모델에서도 염증을 억제한다고 입증되었다(문헌 Kim JS, Jobin C. 2005. The flavonoid luteolin prevents lipopolysaccharide-induced NF-kappaB cignalling and gene expression by blocking IkappaB kinase activity in intestinal epithelial cells and bone-marrow derived dendritic cells. Immunology Jul 115(3_ : 375-387; Kim HP, Son KH, Kim JS, Kang SS. Flavonoids : potential anti-inflammatory agents. Natural Products Sci 58(9) :537-552; Lee SJ, Son KH, Chang HW, Do JC, Jung KY, Kang SS, Kim HP. 1993. Antiinflammatory activity of naturally occurring flavone and flavonol glycosides. Arch Pharm Res 16(1) : 25-28 참조). 따라서 무청 추출물의 총 플라보노이드 함량은 100g 당 0.19g를 대조군으로 사용된 갈산(Galic acid)과 비교했을 때 항산화 활성이 높은 것을 알 수 있으며, 이들 성분이 궤양성 대장염의 증상 완화에 도움을 주었음을 알 수 있다. Flavonoids have been shown to have potential as anti-inflammatory agents in many inflammatory studies, particularly in the LPS-stimulated rat fibroblasts, and the activity of NF-kB and the intestinal epithelial cells IEC18 and myeloid dendritic cells Inhibited the IkB kinase activity and TNF-secretion and also suppressed inflammation in the Crohn's disease model (Kim JS, Jobin C. 2005. The flavonoid luteolin inhibits lipopolysaccharide-induced NF-kappaB cignalling and gene expression by blocking IkappaB kinase Kang SS, Flavonoids: Potential anti-inflammatory agents. Natural Products Sci 58 (9): 371-377. Arch Pharm Res 16 (1): 25-35, 1992. The anti-inflammatory activity of naturally occurring flavonol and flavonol glycosides is shown in Table 1. [ 28). Therefore, the total flavonoid content of Wuchung extract is 0.19g per 100g, which is higher than that of Galic acid used as a control, and these components are useful for relieving symptoms of ulcerative colitis And the other.
2) 던칸 다중검정에 의한 그룹들 간의 유의적인 차이(p<0.05) 확인1) Each value is expressed as the mean standard deviation of triplicate experiments.
2) Significant difference between groups by Duncan multiple test (p <0.05).
(4)과산화물 제거효소(SOD) 유사 활성(4) peroxide-eliminating enzyme (SOD) -like activity
SOD 유사활성 측정 결과, 무청 추출물이 63%, 대조군으로 사용한 BHT가 36%의 활성을 가진 것으로 나타났다. SOD-like activities of the extracts were 63% and 36%, respectively.
(5)ABTS + 라디칼 소거활성(5) ABTS + radical scavenging activity
무청 추출물과 신선초 추출물의 ABTS 양이온 라디칼 소거능을 100㎍/㎖의 농도에서 측정한 결과, 무청 추출물이 17%로 가장 높았으며, 대조군으로 사용된 아스코르빈산이 13%의 활성을 가진 것으로 나타났다. As a result of measuring ABTS cation radical scavenging ability of Wuchung extract and Chinese persimmon extract at 100 μg / ㎖ concentration, ascorbic acid used as a control group had the highest activity of 17%, and 13% of ascorbic acid used as a control group.
(6) 무청의 항산화 성분과 항산화 활성 간의 상관관계(6) Correlation between antioxidant activity and antioxidant activity
플라보노이드 성분과 DPPH, ABTS 등의 실험 결과 간에 유의한 상관관계가 있는 것으로 나타났다. 선행연구에서 플라보노이드 화합물이 비타민 E에 비해 3배 내지 5배 이상의 항산화 작용을 나타내었다고 보고한 것을 볼 때(문헌 Kim DO, Lee KW, Lee HJ, Lee CY. 2002. Vitamin C equivalent antioxidant capacity(VCEAC) of phenolic phytochemicals. J Agric Food Chem 50 : 3713-3717 참조), 본 실험에서 다른 계열의 폴리페놀 화합물보다 플라보노이드 화합물의 양이 더 많이 존재하며, 이들이 궤양성 대장염 억제 활성에 큰 영향을 미쳤다는 결론은 내릴 수 있다.There was a significant correlation between flavonoid components and experimental results such as DPPH and ABTS. In a previous study, it was reported that flavonoid compounds showed 3 to 5 times more antioxidative activity than vitamin E. (Kim DO, Lee KW, Lee HJ, Lee CY 2002. Vitamin C equivalent antioxidant capacity (VCEAC) of phenolic phytochemicals. J Agric Food Chem 50: 3713-3717). The conclusion was that the amount of flavonoid compounds was greater in this experiment than in other polyphenols, and that they had a significant effect on ulcerative colitis inhibitory activity I can get off.
2)항산화 활성을 가진 무청 추출 농축액의 궤양성 대장염 억제 효과 규명2) Identification of the anti-ulcerative colitis inhibitory effect
(1)대장염증 유도 전과 후의 체중 증가량, 식이섭취량, 식이효율, 음용수 및 DSS 섭취량(표 7 내지 표 9 참조)(1) Weight gain, dietary intake, dietary efficiency, drinking water and DSS intake before and after induction of colonic inflammation (see Tables 7 to 9)
무청 추출물 첨가 사료 섭취군의 염증 유도 전과 후에도 식이 섭취량과 체중 증가량이 대조군보다 높았다. Dietary intake and body weight gain before and after induction of inflammation in rats fed with Wuchung extract were higher than those of the control group.
DSS로 대장염증을 유도한 뒤로 무청을 제외한 대조군에서 몸무게와 식이섭취량, 식이효율이 감소하였다.After induction of colonic inflammation with DSS, body weight, dietary intake, and dietary efficiency were decreased in the control group except the control group.
특히 주목할 점은 대조군이 식이섭취량과 몸무게 증가량이 모두 급격히 감소한데 반해, 무청 추출물 첨가 사료 섭취군은 식이 섭취량은 대장염 유도전과 근접한 수치로 감소하였으며, 무게증가량이 역시 대장염 유도전과 비슷한 수치를 보였다. 이는 무청이 가진 항산화 활성과 연관이 깊다. 다른 선행연구에서 AFB1과 항산화 비타민 투여 시, 체중, 장기 및 식이섭취량을 비교하였더니, AFB1 단독 투여군에서는 체중이 감소하였으나, 항산화 비타민 C, E의 혼합 투여군에서는 체중감소에 대해 유의성이 나타나지 않았으며, 식이섭취량 역시 AFB1에서는 급격히 하강하였으나, 항산화 비타민 투여군에서는 식이섭취량 역시 감소하지 않았다고 보고하였다(문헌 Park SJ, Kim HK, Chung DH. 2002. The effect of antioxidant vitamins on residual Alfatoxin B1 in mice serum. J Korean public Health Assoc28(1) 81-88 참조).Particularly noteworthy was the decrease in both the dietary intake and the body weight gain in the control group, while the dietary intake in the dietary supplement group with wuchu extract decreased to a value close to that before induction of colitis, and the weight increase was also similar to that before induction of colitis. This is closely related to the antioxidant activity of Wuqing. In the previous study, weight, organ and dietary intake of AFB1 and antioxidant vitamins were compared. In the AFB1 alone group, body weight was decreased, but in the mixed group of antioxidant vitamins C and E, The intake was also significantly decreased in AFB1, but in the antioxidant vitamin-treated group, the dietary intake was also not decreased (Park SJ, Kim HK, Chung DH 2002. The effect of antioxidant vitamins on residual serum Alfatoxin B1 in mice. Assoc 28 (1) 81-88).
따라서 무청의 항산화 활성을 가진 기능성 성분들이 염증으로 체중감소, 탈수 등의 현상을 완화시킨 것으로 가설을 확인할 수 있었다. Therefore, it was hypothesized that the functional ingredients with anti-oxidant activity of wheat germs relieve weight loss and dehydration by inflammation.
하기 표7은 대장염 미유도 기간 중의 생쥐의 체중 증가, 음식 섭취 및 음식 효율을 나타내고 있다.Table 7 below shows the weight gain, food intake and food efficiency of mice during the period of colitis infestation.
(g/일)Weight gain
(g / day)
(g/일)Food intake
(g / day)
2) 던칸 다중검정에 의한 그룹들 간의 유의적인 차이(p<0.05) 확인
3) 음식 효율 = 체중 증가(g)/ 음식 섭취(g)
6) 실험군(n=52)은 다음과 같음:
N(13): 대조 식이 급이군
C(13): 3% DSS + 5% 대조 식이 급이군
무청(13): 3% DSS + 5% 무청 추출물 분말 급이군1) Average standard deviation
2) Significant difference between groups by Duncan multiple test (p <0.05).
3) Food efficiency = weight gain (g) / food intake (g)
6) The experimental group (n = 52) was as follows:
N (13): The control diet is rapid.
C (13): 3% DSS + 5% control diet
Wuqing (13): 3% DSS + 5% Wuchuan extract powder
하기 표 8은 대장염 유도 기간 중의 생쥐의 체중 증가, 음식 섭취 및 음식 효율을 나타내고 있다.Table 8 below shows the weight gain, food intake and food efficiency of mice during the induction period of colitis.
(g/일)Weight gain
(g / day)
(g/일)Food intake
(g / day)
2) 던칸 다중검정에 의한 그룹들 간의 유의적인 차이(p<0.05) 확인
3) 음식 효율 = 체중 증가(g)/ 음식 섭취(g)
4) 실험군(n=52)은 다음과 같음:
N(13): 대조 식이 급이군
C(13): 3% DSS + 5% 대조 식이 급이군
무청(13): 3% DSS + 5% 무청 추출물 분말 급이군1) Average standard deviation
2) Significant difference between groups by Duncan multiple test (p <0.05).
3) Food efficiency = weight gain (g) / food intake (g)
4) The experimental group (n = 52) was as follows:
N (13): The control diet is rapid.
C (13): 3% DSS + 5% control diet
Wuqing (13): 3% DSS + 5% Wuchuan extract powder
하기 표 9는 5일간의 대장염 유도 기간 동안의 DSS/물 섭취를 나타내고 있다.Table 9 below shows the DSS / water uptake during the 5 day colitis induction period.
(㎖/5일)DSS / water intake
(Ml / 5 days)
(㎎/g)DSS / water intake
(Mg / g)
2) DSS 부하 = 총 음료 섭취(㎖) DSS 농도(㎎/㎖) / 초기 체중(g)
3) 던칸 다중검정에 의한 그룹들 간의 유의적인 차이(p<0.05) 확인1) Average standard deviation
2) DSS load = total beverage intake (ml) DSS concentration (mg / ml) / initial weight (g)
3) Significant difference between groups by Duncan multiple test (p <0.05).
(2) 대장염 유발 전후의 체중변화량(2) Weight change before and after colitis induction
2) 던칸 다중검정에 의한 그룹들 간의 유의적인 차이(p<0.05) 확인1) Average standard deviation
2) Significant difference between groups by Duncan multiple test (p <0.05).
대장염증 발병 전 무청 추출물 섭취군의 경우, 정상군, 대조군에 비해 체중 증가량이 적었으나, 대장염증 발병 후에는 지속적인 무게증가와 식이 섭취량을 보여 이것이 평균 체중에 영향을 주었다고 판단된다. 이는 무청 추출물의 항산화 성분이 염증을 억제하고, 무청 추출물의 식이섬유 단당류가 분해되면서 대장 내 세포에 연료로 사용되어 대장의 부담을 덜어 실험동물의 장 기능 개선에 긍정적인 영향을 미치었기 때문으로 보고 있다(문헌 Jang HS, Ahn JM, Ku KH, Rhee SJ, Kang SK, Choi JH. 2008. Effect of Radish Leaves Powder on the Gastrointestinal Function and Fecal Triglyceride and Sterol Excretion in Rats Fed a Hypercholesterolemic Diet. J Korean Soc Food Sci Nutr 37(10) : 1258-1263 참조; 문헌 Carol Byrd-Bredbenner, Gail Moe, Donna Beshgetoor, Jacqueline Berning. 2010. Nutrient analysis of varying socioeconomic status home food environments in New Jersey Appetite 54 : 384-389 참조). In the case of intestinal extract, the weight gain was smaller than that of the normal group and the control group. However, after the onset of colon inflammation, the weight gain and the dietary intake were observed to be influential on the average weight. This is because the antioxidant component of WuQi extract inhibits inflammation and decomposes dietary fiber monosaccharide of WuQi extract, which is used as a fuel for intestinal cells, thereby relieving the burden of bowel, thus positively affecting the improvement of intestinal function of experimental animals 2008. Effect of Radish Leaves Powder on Gastrointestinal Function and Fecal Triglyceride and Sterol Excretion in Rats Fed A Hypercholesterolemic Diet J Korean Soc Food Sci See Caroline Byrd-Bredbenner, Gail Moe, Donna Beshgetoor, and Jacqueline Berning. Nutr 37 (10): 1258-1263.
3)대장길이의 변화3) Change in length of colon
청 추출물 섭취군의 경우, 정상군보다 대장의 길이가 더 길은 것으로 나타났으며, 정상군에 비해 DSS 단독 처리 된 대조군의 대장이 축소된 모습이었는데, 이는 DSS가 점막 상피세포에 직접 독성을 나타내어 점막 장벽의 완전성에 영향을 주기 때문으로 생각된다(문헌 Jung HC. 2001. Animal model for inflammatory bowel disease. Korean J Gastroenterol 37(2) : 69-75; Wirtz S,Neurath MF. 2007. Mouse models of inflammatory bowel disease. Adv Drug Deliv Rev 59(11) : 1073-1083 참조). In contrast, the DSS-treated group showed a longer colon length than the normal group, and the DSS-treated control group showed a reduced size of the colon compared to the normal group, indicating that the DSS was directly toxic to the mucosal epithelium, (Jung HC 2001. Animal models for inflammatory bowel disease. Korean J Gastroenterol 37 (2): 69-75; Wirtz S, Neurath MF 2007. Mouse models of inflammatory bowel disease. Adv Drug Deliv Rev 59 (11): 1073-1083).
청 추출물의 항산화 성분이 염증을 억제하고 장내 기능을 개선하였기 때문이다. 하기 표 11은 대장의 변화를 나타내고 있다.Antioxidant components of blue extract inhibited inflammation and improved intestinal function. Table 11 below shows changes in the colon.
2) 던칸 다중검정에 의한 그룹들 간의 유의적인 차이(p<0.05) 확인1) Average standard deviation
2) Significant difference between groups by Duncan multiple test (p <0.05).
(4)장내 미생물 변화 비교(4) Comparison of intestinal microbial changes
16S rDNA V3을 표적(target)으로 한 338f-GC와 518r 프라이머쌍(primer pair)으로 박테리아 유전자(bacterial genomic) DNA를 중합효소 연쇄반응(PCR)하여 약 180bp의 단편(fragment)을 얻었으며, 변성세척겔에 전기영동하여 다양한 장내세균총을 확인하였다. 사진(도 1)에서 왼쪽부터 정상군, 대조군, 무청 추출물 급이군이다.A fragment of approximately 180 bp was obtained by polymerase chain reaction (PCR) of bacterial genomic DNA with 338 f-GC and 518 r primer pair targeting 16S rDNA V3, A variety of intestinal flora was identified by electrophoresis on the washing gel. In the photograph (FIG. 1), normal group, control group, and wuchu extract-fed group from the left.
1번 밴드는 비-배양 박테리아(Uncultured bacterium) 80%, 2번 밴드는 헬리코박터 카나덴시스(H. canadensis) 97%, 3번은 비배양 박테리아 80%, 4번은 비배양 피르미쿠트 박테리움(Uncultured Firmicutes bacterium) 93%, 5번 밴드는 헬리코박터 파이롤리(H. pylori) 92% 일치하는 것으로 나왔다. 2번과 5번 밴드는 유해균인 헬리코박터 균주로 무청에서는 5번만 나와, 무청 추출물에서 헬리코박터 균주의 발현을 감소시킨 것을 알 수 있었다. The first band is 80% of the uncultured bacterium, the second band is 97% of the H. canadensis , the third is 80% of the non-cultured bacteria, the 4th is the uncultured bacterium, Firmicutes bacterium ) 93%, and band 5 was found to be 92% identical to Helicobacter pylori ( H. pylori ). The second and fifth bands were found to be Helicobacter strains, which are harmful bacteria, and showed only 5 times in Wuqing, and decreased the expression of Helicobacter strains in Wuqing extract.
(5) 대장 내 염증세포의 조직학적 소견(5) Histological Findings of Intestinal Inflammatory Cells
대장 조직 절편 중 무작위로 선별하여 조직검사를 한 결과, 도 2(결장 내 염증 세포의 외양)에 나타낸 바와 같이, A는 정상군으로 염증단계가 2등급(grade 2)이나 깨끗한 모습을 띄우는데 반해, B는 대조군은 4등급으로 점막하층에 많은 염증세포가 침윤해 있고 점막상피 증식이 뚜렷하게 관찰되었다. 무청 추출물 분말 섭취군은 C는 1등급에 해당되며 점막고유층에 소수의 염증세포 침윤이 관찰되었으며, 점막상피는 약한 과형성이 있지만 전반적으로 대장염 호전 효과가 관찰되었다. As shown in Fig. 2 (appearance of inflammatory cells in the colon), A was a normal group and the inflammation stage was grade 2 or clean, while the colon tissue was randomly selected and histologically examined. , And the control group was grade 4, and many infiltrating inflammatory cells were observed in the submucosal layer and mucosal epithelial proliferation was clearly observed. There was a small number of inflammatory cell infiltration in the mucosal layer of the mucosa, and C mucosal inflammation was observed in the mucosal epithelium with weak hyperplasia.
도 2에서 A는 대조 급이군이고, B는 3% DSS + 대조 급이군이고, C는 3% DSS + 5% 무청 추출물 분말 급이군이다.In FIG. 2, A is the control group, B is the 3% DSS + control group, and C is the 3% DSS + 5%
(6) 대장 내 염증 세포수 측정(6) Measurement of the number of inflammatory cells in the colon
표 12에 나타난 바와 같이, 대조군의 대장의 조직절편의 대부분에서 염증세포 출현이 뚜렷이 인지되었으며, 대조군과 비교했을 때 무청 추출물에서 염증세포가 감소하였음을 알 수 있었다. 따라서 무청 추출물의 장 점막 보호효과를 확인할 수 있었다.As shown in Table 12, the appearance of inflammatory cells was clearly recognized in most of the tissue sections of the colon of the control group, and the inflammatory cells were decreased in the extracts of Wuchung, compared to the control group. Therefore, we could confirm the protective effect of Wuchung extract on intestinal mucosa.
2) 던칸 다중검정에 의한 그룹들 간의 유의적인 차이(p<0.05) 확인1) Average standard deviation
2) Significant difference between groups by Duncan multiple test (p <0.05).
5.결론5. Conclusion
무청 추출물의 항산화 활성을 가진 기능성 성분들로 인해 염증으로 인해 발생하는 산화 스트레스를 줄이는 역할을 함으로써 궤양성 대장염증 발병 시 동반하는 혈변 및 체중감소, 탈수 현상을 완화시킬 수 있음을 확인할 수 있었다.The functional components with antioxidant activity of the extracts of Wuchung can reduce the oxidative stress caused by the inflammation, and thus it is possible to alleviate the accompanying blood loss, weight loss and dehydration in the case of ulcerative colitis.
본 발명은 항산화 효과 등을 기대할 수 있는 사료 등을 제조하고, 이를 유통하는 축산업에서 이용될 수 있다.The present invention can be used in an animal husbandry industry in which diets and the like can be expected to have antioxidative effects and the like and are distributed.
이상에서 본 발명은 기재된 구체예에 대해서만 상세히 설명되었지만 본 발명의 기술사상 범위 내에서 다양한 변형 및 수정이 가능함은 당업자에게 있어서 명백한 것이며, 이러한 변형 및 수정이 첨부된 특허청구범위에 속함은 당연한 것이다.While the invention has been shown and described with reference to certain exemplary embodiments thereof, it will be understood by those skilled in the art that various changes and modifications may be made without departing from the spirit and scope of the invention as defined by the appended claims.
(도면 부호 없음)(Without reference numerals)
Claims (9)
상기 무청 추출물은 무청을 추출하여 제조되며, 이때 추출비율은 70% 내지 90%(v/v)인 에탄올 90 내지 99중량% 및 상기 무청의 건조분말 1 내지 10중량%의 비율로 혼합하고, 상온에서 40 내지 54시간 동안 현탁시킨 후, 다시 20 내지 28시간 동안 침지시킨 후, 여과하는 과정을 1 내지 5번 반복하여 얻은 추출물을 합하여 1 내지 20℃의 온도조건에서 농축시킨 농축액임을 특징으로 하는 항염 및 항산화를 위한 사료 조성물.A feed composition for anti-inflammation and antioxidation comprising an extract of Wuchuan as an active ingredient,
The extract of Wuchuan is prepared by extracting the extracts, and the extraction ratio is 90 to 99% by weight of ethanol of 70% to 90% (v / v) and 1 to 10% At a temperature of 1 to 20 DEG C, and the extracts obtained by repeating the step of filtration for 1 to 5 times are mixed and concentrated at a temperature of 1 to 20 DEG C. And a feed composition for antioxidation.
상기 농축액은 동결건조되어 추출분말로 제조되며, 동결 건조된 추출분말은 다시 70% 내지 90%(v/v)인 에탄올에 용해시켜 사용할 수 있게 한 것을 특징으로 하는 항염 및 항산화를 위한 사료 조성물.
The method of claim 5,
Wherein the concentrate is lyophilized to prepare an extract powder, and the lyophilized extract powder is dissolved again in 70% to 90% (v / v) ethanol to be used.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020140046766A KR101706817B1 (en) | 2014-04-18 | 2014-04-18 | Composition comprising radish leave extract for anti-inflammatory and anti-oxidant |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020140046766A KR101706817B1 (en) | 2014-04-18 | 2014-04-18 | Composition comprising radish leave extract for anti-inflammatory and anti-oxidant |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20150120740A KR20150120740A (en) | 2015-10-28 |
KR101706817B1 true KR101706817B1 (en) | 2017-02-16 |
Family
ID=54428887
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020140046766A Active KR101706817B1 (en) | 2014-04-18 | 2014-04-18 | Composition comprising radish leave extract for anti-inflammatory and anti-oxidant |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101706817B1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190036330A (en) | 2017-09-27 | 2019-04-04 | 서원대학교산학협력단 | Anti-oxidant Composition Comprising Heated Radish Extract |
KR20210082044A (en) | 2019-12-24 | 2021-07-02 | 제주돌담뜰 농업회사법인(주) | Composition for preventing or improving of skin wrinkle or skin aging comprising roasted dried-radish-slices extracts, and healthy food comprising the composition |
KR20210105089A (en) | 2020-02-18 | 2021-08-26 | 서원대학교산학협력단 | Composition for Prophylaxis of Colon Cancer |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102048434B1 (en) * | 2018-12-18 | 2019-11-25 | 한국식품연구원 | A composition as a prebiotic for improving intestinal microflora containing High-molecular fraction from radish leave |
KR102223635B1 (en) * | 2019-04-26 | 2021-03-05 | 한국식품연구원 | Composition for improvementing, preventing or treating intestinal inflammation or leaky gut syndrome comprising fractions or extract of radish leave |
WO2020130296A1 (en) * | 2018-12-18 | 2020-06-25 | 한국식품연구원 | Composition for improving gut flora, or composition for alleviating, preventing or treating gut inflammation, leaky gut syndrome, obesity, or metabolic intestinal disorders, comprising extract of radish greens |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101069225B1 (en) * | 2008-07-08 | 2011-09-30 | 강화군 | Manufacturing method of turnip concentrate |
KR101148978B1 (en) * | 2010-05-12 | 2012-05-22 | 주식회사 아데나 | Cosmetic Composition for Blocking Ultraviolet-A Comprising Extract of Gracilariopsis Chorda |
KR20120036685A (en) * | 2010-10-08 | 2012-04-18 | 영농조합법인 속리바이오텍 | Extract method of dietary fiber of dried radish leaf and extracted dietary fiber by this method |
KR101469352B1 (en) * | 2013-03-08 | 2014-12-08 | 안동대학교 산학협력단 | An anti-bacterial pharmaceuticals comprising the butanol fraction of raphanus sativus l. leaves extract as an effective component and a health functional food comprising the same |
-
2014
- 2014-04-18 KR KR1020140046766A patent/KR101706817B1/en active Active
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190036330A (en) | 2017-09-27 | 2019-04-04 | 서원대학교산학협력단 | Anti-oxidant Composition Comprising Heated Radish Extract |
KR20210082044A (en) | 2019-12-24 | 2021-07-02 | 제주돌담뜰 농업회사법인(주) | Composition for preventing or improving of skin wrinkle or skin aging comprising roasted dried-radish-slices extracts, and healthy food comprising the composition |
KR20210105089A (en) | 2020-02-18 | 2021-08-26 | 서원대학교산학협력단 | Composition for Prophylaxis of Colon Cancer |
Also Published As
Publication number | Publication date |
---|---|
KR20150120740A (en) | 2015-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Tang et al. | Date fruit: chemical composition, nutritional and medicinal values, products | |
KR101706817B1 (en) | Composition comprising radish leave extract for anti-inflammatory and anti-oxidant | |
C. Hunter et al. | Antioxidant and ‘natural protective’properties of kiwifruit | |
Gawlik-Dziki et al. | Improvement of nutraceutical value of broccoli sprouts by natural elicitors | |
KR20120022795A (en) | Agent for regulating composition ratio of intestinal bacterial flora | |
KR100844185B1 (en) | Fermented Mugwort Tea Manufacturing Method Using Lactic Acid Bacteria | |
Gheisari et al. | Drying method effects on the antioxidant activity of quince (Cydonia oblonga Miller) tea | |
KR20140103622A (en) | The method for manufacturing functional tea product made from onion skin, and the product made by the method | |
Thakur et al. | Optimization of lyophilized microencapsulated phenolic extract concentration for enrichment of yoghurt and effect on chemical parameters, bioactive compounds, antioxidant activity and sensory quality under storage | |
KR101270972B1 (en) | Antifungal composition containing plant extracts | |
KR101661491B1 (en) | Method of manufacturing vegetable juice with improved health functions using Allium Hookeri | |
KR101503429B1 (en) | Preparation method of cassia tora l. with improved antioxidant activity by using roasting | |
KR101231589B1 (en) | Goatsbeard extract or its fraction having antiviral, antioxidative and antimicrobial effects | |
JP2010254594A (en) | Intestinal Bacteroides growth promoter | |
KR20160058205A (en) | Composition for removing hangover comprising fermented rice rinse water | |
KR101231590B1 (en) | Eriobotrya japonica extract or its fraction having antiviral, antioxidative and antimicrobial effects | |
Lim | Fagopyrum esculentum | |
Gumienna et al. | Influence of plant extracts addition on the antioxidative properties of products obtained from green lentil seeds during in vitro digestion process | |
KR20150064521A (en) | Fermented composition comprising bamboo salt and rhynchosia nulubilis | |
KR102720213B1 (en) | A health functional food composition for improving muscle loss or motor ability, including extract of Catalpa bignonioides | |
KR101403354B1 (en) | Method for producing beverage using dandelion | |
KR20150129461A (en) | Sasa quelpaertensis nakai tea and manufacture method thereof | |
KR102814576B1 (en) | A process for the preparation of detox drink and detox drink produced therefrom | |
KR101146115B1 (en) | Beverage containing fermened extract of rhus verniciflura having anticancerous and antioxidative activity, and the preparation method thereof | |
KR102780487B1 (en) | A food composition that helps improve periodontal disease, which consists of gingivitis and periodontitis, by suppressing inflammatory diseases of the gums and bacterial growth in the oral cavity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20140418 |
|
PA0201 | Request for examination | ||
PG1501 | Laying open of application | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20160125 Patent event code: PE09021S01D |
|
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20160729 Patent event code: PE09021S01D |
|
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20170131 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20170208 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20170208 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
PR1001 | Payment of annual fee |
Payment date: 20191122 Start annual number: 4 End annual number: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20201207 Start annual number: 5 End annual number: 5 |
|
PR1001 | Payment of annual fee |
Payment date: 20211125 Start annual number: 6 End annual number: 6 |
|
PR1001 | Payment of annual fee |
Payment date: 20221112 Start annual number: 7 End annual number: 7 |
|
PR1001 | Payment of annual fee |
Payment date: 20231109 Start annual number: 8 End annual number: 8 |
|
PR1001 | Payment of annual fee |
Payment date: 20241111 Start annual number: 9 End annual number: 9 |